

## CURRICULUM VITAE

**Name:** Frank John Emery VAJDA

**Address:** University Department of Medicine and Neuroscience Royal Melbourne Hospital, University of Melbourne, Royal Parade Parkville Vic 3050

**Date of Birth:** 14<sup>th</sup> October 1935

**Place of Birth:** Budapest

**Citizenship:** Australian

**Marital Status:** Married

**Education:** Budapest University High School, Hungary  
Melbourne High School  
Matriculation, 1953  
1955-1960 University of Melbourne  
Graduated December 1960 ( Honours in Medicine)  
(St. Vincent's Hospital Clinical School, Melbourne)

**Honours:** Royal Swedish Order of the Polar Star (. Nordstjaerorden)  
Knight First Class, April 2003.

Peter Bladin Award , Epilepsy Society of Australia 2007

Member of the Order of Australia , AM (General Division)  
26.1.2012

**Present Appointments:**

Professorial Fellow, University of Melbourne, Department of Medicine and Neuroscience, Royal Melbourne Hospital.

Director and Principal Investigator of the Australian Register of Antiepileptic Drugs in Pregnancy

Honorary Senior Research Associate Victorian Neuroscience Centre, University of Melbourne

Honorary Senior Principal Research Fellow,  
Howard Florey Institute of Neurosciences, University of Melbourne

Consultant Physician  
Austin and Repatriation Medical Centre, Heidelberg.

<b>Qualifications:</b>	1960	M.B.B.S. (Melbourne)
	1965	M.R.C.P. (Edinburgh) ( Neurology)
	1967	M.R.A.C.P.
	1972	M.D. (Melbourne)
	1972	F.R.A.C.P.
	1982	F.R.C.P. (Edinburgh)

### **Previous Appointments:**

Professor of Clinical Neuropharmacology, Monash University  
Melbourne 2004-2008

Professorial Fellow, University of Melbourne, Department of  
Medicine, St. Vincent's and Geelong Hospitals. 1999=2008

1997- 2003 Director  
Australian Centre for Clinical Neuropharmacology -  
Raoul Wallenberg Centre,  
St. Vincent's Hospital, Fitzroy, University of  
Melbourne

1997-2004 Senior Principal Grade Neurologist, St.Vincent's  
Hospital Melbourne

1994-1997 Consultant Neurologist  
St. Vincent's Hospital, Fitzroy.

1993-1994 Visiting Neurologist  
Repatriation Hospital, Heidelberg.

1988-1993 Consultant Neurologist,  
Neurological Pharmacologist  
Austin Hospital, Heidelberg.

1980-1986 Consultant Clinical Pharmacologist  
Queen Victoria Medical Centre, Melbourne.

1974-1988 Consultant Neurologist ( Peter Bladin AO)  
Senior Clinical Pharmacologist  
Austin Hospital, Heidelberg.

1973-1974 Senior Lecturer in Clinical Neuropharmacology and  
Therapeutics  
Middlesex Hospital, Medical School, University of  
London. (Professor F. Hobbiger D.Sc.).

1972-1973 Research Fellow, Medical Research Council

Department of Clinical Pharmacology  
 Postgraduate Medical School,  
 Hammersmith Hospital, London.  
 (Sir Colin Dollery, and Sir Alasdare Breckemridge)

- 1968-1971 Research Associate, later Third Assistant  
 Department of Medicine, Royal Melbourne  
 Hospital. (Professor RRH Lovell AO)
- 1967-1968 Clinical School Supervisor  
 Assistant to Dean  
 Royal Melbourne Hospital, Clinical School.
- Associate Assistant  
 Walter and Eliza Hall Institute, Clinical Research  
 Unit, Melbourne.
- 1966 Clinical Assistant Neurology  
 National Hospital for Nervous Diseases,  
 Queens Square, London, Royal Free Hospital,  
 London.
- 1965 Senior Medical Registrar  
 Royal Free Hospital, London.
- 1963-1964 Registrar  
 Repatriation Gen. Hospital, Heidelberg, Vic. Melb.
- 1962 Senior House Officer  
 Royal Children's Hospital, Melbourne.
- 1961 Resident Medical Officer (Professor Carl de  
 Gruchy, Professorial Unit)  
 St. Vincent's Hospital, Melbourne.

### **Invitations to Scientific Meetings and Symposia**

Invitation to join Faculty of 1000, International League Against Epilepsy, Panel for  
 Education 2007

European Neurological Society Rhodes 2007

Goteborg International Meeting on valproate 2005

Congress of the Eur. Neurological Society Barcelona 2004

Meeting of the European FEDERATION OF Neurological societies Paris 2004

Valproate through the ages symposium Goteborg Sweden 2005

Launch of Trileptal, Chairman and Presentation of Basic and clinical pharmacology, Melbourne, August 2002.

Symposium on Motor Neurone Disease, Sydney, 30 May 2002.

Chairman, Paediatric Launch of Topiramate, Melbourne 15 May 2002.

Keynote Speaker. International Meeting Sorrento, Italy 19-21 April 2002, Neuroprotection and Valproate.

Chairman International Scientific Meeting: Extension of the Use of Topiramate, Gold Coast Queensland March 9-11 2002. with B. Schmidt and Roy Twyman

Participant International Symposium on Degenerative Diseases Prague Czech Republic February 26 - March 2002.

Chairman, Satellite Symposium, Optimising Drug Therapy, Epilepsy Society of Australia, Perth 2001.

Invited speaker, Drug Safety - Sydney September 2001  
Canberra September 2001

Chairman, Topomax - Focus on Paediatrics, Melbourne 2001.

Chairman, Epilepsy Society of Australia Scientific Meeting,: Session on Genetics of Seizure Disorders, Adelaide November 1999.

Chairman, Topomax Symposium in association with Epilepsy Society Meeting, Adelaide, November 1999.

Chairman and Co-ordinator, Asian and South Pacific Forum on topiramate, International Video Conference to U.S., Australia and Asia, Sydney, November 1999.

Invited speaker, Foundation Workshop on Pregnancy Registry, Commission of International League Against Epilepsy, International Epilepsy Congress Prague, September 1999.

Invited speaker, Pharmaceutical Society of Victoria, Modern Management of Epilepsy, July 1999.

Chairman, Review of Gabitril, International Meeting with Dr. R. Kalvainainen, Melbourne 1999.

Chairman, Tiagabine Launch, Melbourne and Sydney 1998.

Chairman, Session Merritt and Putnam Symposium 1998., Annual Scientific Meeting of Epilepsy Society of Australia

Epilepsy 1998, Keynote speaker - Trial and Practice and Epilepsy - How do the stars rate? Melbourne 1998.

Visiting Professor and invited speaker, Neurological Society and Epilepsy Society of Philippines, Manila 1998.

Pharmaceutical Society Lectures 1980-1997 on antiepileptics, migraine, headache.

Topiramate in Epilepsy, Terrigal 1997.

Brisbane Health Program, Mervyn Eadie Festschrift: Presentation:Anticonvulsant Jungle 1997.

Multidisciplinary Meeting on Parkinson's Disease, Perth 1997.

Merritt & Putnam Symposium, Brisbane 1997.

Heritage & Science - Gabapentin & Fosphenytoin, Brisbane 1997.

Pharmacy Australia Congress 1997.

Repatriation Hospital Education Seminars 1995.

Austin Hospital Neuroscience Seminars 1993-1995.

Scientific Meeting on Lamotrigine Launch, Coolam 1994.

Invited speaker, Australian Association Neurologists 1994 New Anticonvulsants.

Invited speaker, Victorian Epilepsy Foundation, 1988-1994.

Participant Workshops in Epilepsy, Melbourne 1983-1993.

Symposium of Therapeutic Drug Monitoring (University of Sydney), November 1984.

Invited speaker, "Epilepsy 84". International Meeting on Epilepsy, Sydney 1984.

Symposia on Epilepsy and Pregnancy, Perth, Adelaide and Melbourne 1983.

Invited speaker, Symposium on Drug Monitoring, Sydney 1983.

Australian Association of Neurologists Annual Meeting. Chairman of Sessions on Epilepsy, 1982.

International Congress of Neuropathology, Vienna, Austria 1982.

Neurosciences Meeting, Sydney, January 1982.

First International Congress of Clinical Pharmacology and Therapeutics, London, U.K. 1980.

Invited speaker at Conjoint Symposium of Royal Australasian College of Physicians, Royal Australasian College of Surgeons and Royal College of Physicians and Surgeons of Canada, Sydney 1980.

Victorian Postgraduate Federation speaker at Wangaratta 1980.

Invited speaker, International Symposium on State Epilepticus. National Institute of Health and University College at Los Angeles, November 1980.

Invited speaker, Pharmacokinetic Workshop: Annual Meeting of Australian Society of Clinical and Experimental Pharmacologists, 1980.

Chairman of Session on Clinical Medicine: May Meeting Australian Society Clinical and Experimental Pharmacologists, 1980.

Chairman of Session of Pharmacokinetics and Chemotherapy: 5<sup>th</sup> Annual Session of the International Oncology Society, Nice, France, December 1979.

Victorian Postgraduate Federation speaker at Bendigo 1979.

International Society of Oncology, Chairman of Session on Anticancer Chemotherapy, Nice, France 1979.

Invited speaker at Symposium on Pain: Physiological and Pharmacological Aspects, Melbourne 1979.

Invited speaker at Symposium on Pharmacological Treatment of Epilepsy, Laurundel Hospital, 1979.

Invited speaker on Benzodiazepine Receptors: Department of Pharmacology, Melbourne 1979.

Invited speaker in Hypertension: Pharmaceutical Society, Melbourne 1979.

International Society of Oncology, Chairman of Session on Anticancer Chemotherapy, Nice, France 1979.

Speaker at Symposium on Epilepsy: Adelaide 1978, Hobart 1978, Albury 1978, Geelong 1978.

Symposium on Epilepsy: Pharmacology of Antiepileptic Drugs, Melbourne 1978.

Epilepsy Symposium: Clinical and Pharmacological Aspects of Sodium Valproate, Adelaide 1978.

Pharmaceutical Society: Epilepsy and Migraine, 1978.

Royal Australian College of Physicians and Melbourne Medical Postgraduate Committee: Recent Advances in Medicine, Pharmacokinetics of Anticonvulsants, Royal Melbourne Hospital, 1978.

University of Melbourne, Rowden White Lecturer: Neurology, Ballarat 1977.

Postgraduate Meeting: Temporal Lobe Epilepsy, Bendigo 1977.

I.C.I. Symposium: Atenolol in Hypertension. Comparative Double Blind Clinical Trial of Four Beta Blocking Drugs in the Treatment of Hypertension, Melbourne 1977 and Sydney 1977.

College of General Practitioners: Drug Interactions, Melbourne 1977.

Royal College of Pathologists of Australia: Plasma Levels in Clinical Medicine, Plenary Session, Annual Meeting, 1977.

Invited speaker: Pharmacology Department, Monash University: Blood Levels of Drugs, 1977.

Postgraduate Medical Federation: Drug Interactions in the Elderly, Mount Royal Hospital, 1976.

Symposium: Epilepsy in the Community, Adelaide 1976.

International Symposium: Sodium Valproate, Nottingham, U.K. 1975.

Pharmaceutical Society Symposium: Parkinson's Disease, 1975.

Melbourne, Medical Postgraduate Committee: Clinical Pharmacology for F.R.A.C.G.P., 1967.

### **Membership of Societies and Professional Organisations and External Advisory Roles.**

Member, Editorial Board Drug Research Adis Press 2002-

Member External Review Panel, Adis Publications, Sydney 2001-

Reviewer Therapeutic Guidelines: Drugs in Neurology, 2001- J.Tiller Editor.

Reviewer Australian Medicines Handbook 2001-, Felix Bochner Editor.

Member Management Committee, European-Australian Pregnancy Registry for Women on Antiepileptic Drugs, 2000-

Member Editorial Advisory Board, Current Therapeutics, 2000-

Member, Central Projects Commission, Burden of Epilepsy ILAE 2000.

Member, Advisory Board International League Against Epilepsy Pregnancy Registry projects, 1999-2000.

Member, New York Academy of Sciences 1998-

Investigator in Clinical trials of Antiepileptic Drugs, St. Vincent's Hospital, 1994-1995, involving levetiracetam, gabapentin, pregabalin, tiagabine, vigabatrin.

Convener of Meeting on Antiepileptic Drugs, (Chairman of the Launch meeting of lamotrigine (Coolum, Queensland 1994.

Chairman, Drug Committee, Epilepsy Society of Australia, 1991-

Member of the Board National Epilepsy Association of Australia 1990-1994.

President of Epilepsy Society of Australia, 1990-1994.

Editorial Panel of Australian Prescriber, 1989-

Drug Trials Subcommittee, Austin Hospital, 1989-1993.

Member of Committee of Management of Victorian Epilepsy Foundation, 1989-1991.

Member of Executive of Victorian Epilepsy Foundation, 1989-1991.

External Evaluator, Therapeutic Goods Administration, Drug Safety and Evaluation, Commonwealth Department of Health since 1988-

Senior Investigator, Anticonvulsant Drug Trials, Austin Hospital, Melbourne 1988-1993.

Treasurer, Epilepsy Society of Australia.1988-1991.

Consulting editor, Neuropsychiatric Drug Information Service, Adis Press 1985-1986.

Invited Lecturer in Pharmacology, Monash University, 1980-1993.



Invited Lecturer, Pharmacy College, 1979-2000.

Member of Panel of Reviewers for Project Applications, Australian National Health and Medical Research Council 1976-2002.

Member Research Committee, National Epilepsy Association of Australia. 1985-2001.

Member, Melbourne Teaching Hospitals Drug Utilization Group.

Member of Subcommittee on antiepileptic drug research for International Congress of Pharmacology Planning Group.

Member Editorial Panel, Therapeutic Drug Monitoring Guide.

Co-opted member, Executive Editorial Board of Australian Prescriber.

Examiner in Clinical Pharmacology and Therapeutics, University of Melbourne.

Part-time Lecturer in Pharmacology, University of Melbourne.

Member of Australian Society for Neuropathology.

Lecturer Diploma of Psychological Medicine (Pharmacology), University of Melbourne.

Member of Society for Study of Brain Impairment.

Member of Australian Association of Neurologists.

External Evaluator for Australian Drug Evaluation Committee, Department of Health, Canberra, Australia.

Member of subcommittee of the Therapeutic Goods Standards Committee on University of Parenteral Preparations, Department of Health, Canberra.

Member of Association of Clinical and Experimental Pharmacologists.

Member of the Royal College of Physicians of Edinburgh.

Fellow of the Royal Australasian College of Physicians.

### **Research Grants and Awards:**

Research Grants 1996-2007 from 12 pharmaceutical multinational companies, to establish the Australian Centre for Clinical Neuropharmacol

NHMRC Linkage Grant for study of cognitive effects of antiepileptic drug exposure in infants –( with Dr. A.Wood. D Reutens, V.Anderson.) 2006 for 3 years, \$ 310.000

Peter Bladin Award of the Epilepsy Society of Australia for research and management of epilepsy- November 2007.

Research Award for Study of Motor Neurone Disease with S. Feeney, C. Masters, E. Byrne, 2001, Bethlehem Research Foundation.

Annual Research Grants from Epilepsy Society of Australia and Industry for Pregnancy Registry for Women with epilepsy 1999-2003

Member, Advisory Board, International League Against Epilepsy, Special Projects Commission Collaborative Study on Pregnancy Outcomes, November 2000.

Member, International League Against Epilepsy, Special Projects Commission Collaborative Study on Pregnancy Outcomes, July 1999.

Principal Investigator and National Co-ordinator with Professor Cecilie Lander, Australian Registry of Pregnancy Outcomes, 1998.

Austin Hospital Medical Research Foundation 1985 - Study of benzodiazepines in Epilepsy.

National Health and Medical Research Grant (with Dr. R. A. Smallwood) to study the biliary excretion of endogenous and xenobiotic organic compounds, 1979-1982.

Anti-Cancer Council of Australia (with Professor W.J. Louis) to study pharmacokinetics of cytotoxic drugs, 1979-1982.

Austin Hospital Medical Research Foundation Award (with Dr. G. Mihaly and Dr. R.A. Smallwood) to study hepatic metabolism of drugs, 1979-1982.

Anti-Cancer Council of Victoria Research Grant (with Professor W. J. Louis) to study the clinical pharmacology of cytotoxic drugs, 1976-1979.

National Health and Medical Research Council grant to study brain metabolism of catecholamines (with Dr. B. Jarrott) 1975-1980.

Support to Industry: Continuous support from 1974-1993 by industry in area of antiepileptic therapy in project and therapy related research at Austin Hospital.

Australian Brain Foundation Grant (with Dr. G.A. Donnan). Experimental studies on Parkinson's Disease.

Wellcome Travel Grant to U.K., 1971.

**Teaching Interests and Experience:**

- 1994- 2003 Lecturer in Neuropharmacology, Pharmacy College, Monash.
- 2006-7 Lecturer to Psychology Students Monash University
- 1994-2002 Lecturer to students in 4<sup>th</sup>, 5<sup>th</sup> year of medical course, St. Vincent's Hospital.  
Postgraduate Lecturer to Pharmaceutical Society of Victoria and Neurology Consultant on neuropharmacological aspects of therapeutics, St. Vincent's Hospital.
- 1980- 2008 Lecturer to Pharmaceutical Society of Victoria
- 1990- Chairing and Participation in Scientific Meetings and Teaching Symposia on Drug Safety and Therapeutics in Neurology.
- 1980-1994: Lecturer in Neurology - fourth, fifth and final year students, University of Melbourne. Lecturer in Clinical Pharmacology and Therapeutics, final year. Tutor for F.R.A.C.P Part 1 Candidates. Tutor for candidates for D.P.M. and R.A.C. Physh. Lecturer, Victorian College of Pharmacy. Invited Lecturer, Department of Pharmacology, Monash University, 1979-1994.
- 1975-1988: Lectures in Clinical Pharmacology, 5<sup>th</sup> year M.B.B.S. students.
- 1975-1980: Lecturer in Pharmacology for Postgraduate Diploma of Physiological Medicine, Department of Pharmacology. Lecturer - Demonstrations on drug evaluation (DPM students). Lectures in Neurology and Clinical Pharmacology F.R.A.C.P. training program. Rowden While Lecturer, University of Melbourne to Ballarat Hospital.  
Invited speaker post-graduate Committee and Royal Australasian College of Physicians Seminar on Recent Advances in Neurology. 14 years continuous experience in postgraduate training of Registrars for F.R.A.C.P. examinations in medicine and neurology. Examiner in Pharmacology 4<sup>th</sup> year M.B.B.S. 1971. Examiner in Clinical Pharmacology written examinations 1977. Invited speaker Pharmaceutic Society Symposia 1975-1996.
- 1973: Lecturer in Clinical Pharmacology, Middlesex Hospital, Medical School, London, 5<sup>th</sup> year M.B. students.
- 1972: Therapeutic Teaching Seminars, Royal Postgraduate Medical School, Hammersmith Hospital, London.
- 1969-1971: Weekly Therapeutics Seminars final year M.B.B.S. students, Royal Melbourne Hospital. Inpatient Ward rounds for 3 months annually in Department of Medicine, Royal Melbourne Hospital. Lectures in Pharmacology, Department of Pharmacology, University of Melbourne.

- 1967-1968: Clinical Supervisor, Royal Melbourne Hospital Clinical School, Tutor to 4<sup>th</sup> year students, Royal Melbourne Hospital. Weekly ward round for 5<sup>th</sup> year students, Walter and Eliza Hall Institute and Royal Melbourne Hospital Clinical Research Unit.
- 1965-1966: Teaching rounds - bi-weekly to 5<sup>th</sup> year students, Royal Free Hospital, University of London.
- 1965: Tutor introductory medicine 4<sup>th</sup> year. Royal Melbourne Hospital clinical school.
- 1964: General medicine tutorials to M.B.B.S. Final year students.

**Students Supervised for Higher Qualifications:**

Terence J. O'Brien MD	1999
Mark J. Cook MD	1998
Simon Scharf M.D.	1998
Lionel Genghis Harris Ph.D.	1986
J. Papanicolaou Ph.D.	1985
Samuel F. Berkovic MD	1982
Nicholas Christophidis Ph.D.	1980
George W. Mihaly Ph.D.	1980

**Links with Industry:**

Member of Medical Advisory Boards of Parke Davis-Pfizer, Aventis, UCB Pharma., Roche.

Chair of Medical Advisory Board, Glaxo-Wellcome, Janssen Cilag, Sanofi Synthelabo, Novartis.

Australian Centre for Clinical Neuropharmacology, supported by a consortium of 12 pharmaceutical companies in 2001.

Member Advisory Board, Hoechst Marion Roussel, 1996-99.

Consultant on Expert report in Neuropharmacology, Reckitt and Colman, Australia.

Member, Scientific Committee, Merritt and Putnam Lectures Parke Davis.

Advisor, Parke-Davis on Antiepileptic drugs.

Member, Roche Parkinson's Disease National Advisory Board, 1995-1997.

Chairman, Topiramate Advisory Board, 1995-2002.

Chairman, Lamictal Advisory Board Glaxo-Wellcome, 1991-1998.

Chairman Trileptal Advisory Board 2003 Novartis

Member Keppra Advisory Board UCB Pharma

Member Stalevo Advisory Board Novartis

**Links with Drug Evaluation:**

External Evaluator of clinical data on 18 new drugs submitted for approval since 1990-present, Therapeutic Goods Administration, Drug Safety and Evaluation, Commonwealth Department of Health, Canberra.

### **Projects and Research Protocols**

Studies in relation to valproate and polycystic ovaries (Dr. A. Tanaghow and Dr. B. Jean-Francois). Paper presented at Scientific Meeting of Epilepsy Society October 2001)

Study of mitochondrial function in epilepsy (Dr. B. Jean-Francois).

Study of neuroprotection in neuromuscular disease. A novel study in degenerative disease in collaboration with Professor E. Byrne. Paper Submitted to Aust. J. Internal Medicine Sept. 2003.)

Evaluation of aripiprazole, a new antipsychotic drug in treatment of mania psychosis and depression in collaboration with St. Vincent's Hospital Psychiatric Services (Associate Professor A. Tanaghow). Project concluded 2002.

Studies on visual field functions in patients on tiagabine, lamotrigine and carbamazepine monotherapy. Australian arm of an international study, concluded 2001.

Clinical trial of levetiracetam, a new antiepileptic drug, multicentre international study. Trials concluded 2003, monotherapy trials pending. Published.

Studies of chronic daily headache treated with gabapentin, with Dr. John Heywood, P.Spira and R. Beran. Published.

Outcome studies in multiple sclerosis ( Professor Trevor Kilpatrick, Director of Victorian Neurosciences Centre. Abstract presented in Paris, 2002, Congress of European Neurological Society

Study of biochemical interactions between lamotrigine and valproate with Professor A. Dickinson and Professor W. Hooper, University of Queensland. (Dr. Carlo Solinas PhD. Student)

Protocol for evaluation of new AED's.

Establishment of a protocol to use a pharmacological animal model of primary generalised seizures to investigate the exacerbation of seizures by carbamazepine and other antiepileptic medications, and the possible effects of gender and sex hormones.

Collaboration with Professor Bevyn Jarrott, Joanne O'Neill, Rob Widdop, The Department of Pharmacology, Monash University. Published

Prospective study of the incidence, risk factors and consequences of the local cutaneous adverse reaction, termed the 'purple glove limb syndrome' following the intravenous administration of phenytoin at St. Vincent's Hospital. Collaboration with Ms. H. Matthews, Pharmacy Department, St. Vincent's Hospital, Melbourne. Published

Collaboration with Dr. Dennis Morgan, The Victorian Pharmacy College.

Study of the relationship between plasma levels of lamotrigine and its clinical efficacy and toxicity. (Published and presented European Neurol. Society Annual Meeting Nice 1999.

Double blind study of remacimide vs. carbamazepine for newly diagnosed partial epilepsy. Collaboration with Dr. Richard Stark, Department of Neurology, The Alfred Hospital and Professor M.J. Eadie, Brisbane (1999)

Double blind placebo controlled study of remacimide as an add-on medication in intractable partial epilepsy  
Double blind placebo controlled study of pregabalin for intractable post-herpetic neuralgia. Collaboration with Dr. Andrew Muir, the Centre for Pain Management, St. Vincent's Hospital, Melbourne. 1999-2003

Prospective survey of the incidence of visual field defects in patients who are started on a new antiepileptic medication for inadequately controlled epilepsy  
Establishment of an Australian registry on the outcomes of pregnancies in women taking anti-epileptic drugs in pregnancy. Nationwide collaboration, with Professor C. Lander, The University of Queensland. 1999- Completed 2003

Establishment of a Registry of Porphyria, with a focus on neurological disorders (Dr. Carlo Solinas MD, 2003-) Collaboration with Professor Kilgarny, Alfred Hospital Melbourne, Department of Psychiatry to establish a registry of antipsychotic drug effects in women in pregnancy. Funds are sought from Rotary International

Collaboration with Professor Helen Herman, Director of Psychiatric Services St. Vincent's Hospital and Dr. M. Salzberg, to study Depression in Parkinson's Disease. (2003- ) Published

Continued collaboration with Associate Professor T. J. O'Brien MD, former Deputy Director of the Raoul Wallenberg Centre to study seizure aggravation by antiepileptic drugs in an experimental model ( 2000- ) Published.

Study of potentially teratogenic metabolites of sodium valproate in women with epilepsy in pregnancy, based on papers already presented in Chicago, Philadelphia, Sydney and Brisbane at Scientific Meetings of the American Epilepsy Society and of the Australian Epilepsy Society and the Australian Association of Neurologists. (In collaboration with Professor M. J. Eadie AO, Prof. Cecilie M Lander, A. Prof. T.O'Brien MD, BAF, and Professor Richard Cotton DSc, Director of the Australian Genetics Mutation Centre.

**PUBLICATIONS (June 2006)****A. BOOKS**

- 1 Vajda FJE, Donnan GA (eds).  
*Refractory epilepsy.* Epilepsy Society of Australia publication.  
York Press (Melbourne) 1984.
- 2 Donnan GA, Vajda FJE (eds).  
*Problem areas in acute stroke management.* Stroke Society publication.  
York Press (Melbourne) 1985.
- 3 Vajda FJE, Donnan GA (eds).  
*Grey areas in epilepsy.* Epilepsy Society of Australia publication.  
York Press (Melbourne) 1986.
- 4 Vajda FJE, Donnan GA (eds).  
*Deprenyl - pharmacology and clinical status.*  
York Press (Melbourne) 1987.
- 5 Donnan GA, Vajda FJE (eds).  
*Perspectives in stroke.* Stroke Society publication.  
York Press (Melbourne) 1987.
- 6 Bladin PB, Donnan GA, Vajda FJE (eds).  
*Epilepsy and driving.* Epilepsy Society of Australia publication..  
(Melbourne) 1988.
- 7 Vajda FJE, Donnan GA, Berkovic SF (eds).  
*Epilepsy in Focus.*  
Epilepsy Society of Australia publication (Melbourne) 1988.
- 8 Donnan GA, Berkovic SF, Vajda FJE (eds).  
*Stroke.* Stroke Society publication. 1989.
- 9 Bladin PF, Berkovic SF, Vajda FJE, Donnan GA (eds).  
*Epilepsy Australia: Blueprint for the 90's.*  
ESA Publication 1989.
- 10 Gourlay R, Vajda FJE (eds).  
*A Travellers' Handbook for Person with Epilepsy.*  
International Bureau for Epilepsy. publication.  
Published in Holland 1989.
- 11 Vajda FJE, Berkovic SF, Donnan GA (eds).  
*Epilepsy Update.* Epilepsy Society of Australia publication. 1989.
12. Donnan GA, Fabinyi GCA and Vajda FJE Eds)  
Stroke for the 90's  
Published by the Australasian Stroke Society (1992).



- 13 Eadie MJ, Vajda FJE (eds).  
*Handbook of Experimental Pharmacology Vol. 138*  
*Antiepileptic Drugs Pharmacology and Therapeutics*  
 Springer-Verlag, Berlin, Heidelberg, New York 1999; pp.663 pages

**B. CHAPTERS: June 2006**

1. Williams FM, Vajda FJE, Breckenridge A, Davidson S, Flaconer MA. *Relationship between brain, CSF and plasma concentrations of anticonvulsant drugs in man.* In: Harris, Mawdsley (eds). *The natural history of management of epilepsy. Proceedings of Hans Berger Centenary Symposium.* Raven Press, Edinburgh, 1974;381-401.
2. Vajda FJE, Morris P, Drummer O, Bladin PF. *Studies on sodium valproate - a new anticonvulsant.* In: Legg (ed). *Clinical and pharmacological aspects of sodium valproate (Epilim) in the treatment of epilepsy.* MCS Consultants, Tunbridge Wells 1976;92-100.
3. Vajda FJE, Bladin PF. *1970-1979 A decade of progress in the treatment of epilepsy.* In: Walsh K (ed). *Melbourne University Press, 1979 presented at the University of Melbourne 4<sup>th</sup> Conference on Brain Impairment, (Nov) 1979;229-236.*
4. Vajda FJE, Chambers B, Bladin PF. *Brain impairment in Parkinson's disease.* 5<sup>th</sup> Annual Conference in Brain Impairment, University of Sydney, (Oct.) 1980.
5. Vajda FJE. *Valproic acid in the treatment of status epilepticus.* In: Delgado Escueta AV, Wasterlain CG, Trieman DM, Porter RJ (eds). *Status Epilepticus, Advances in Neurology,* Raven Press, New York, 1983;34:520-529.
6. Vajda FJE. *Brain and peripheral concentration of anticonvulsants.* In: Doyle AE, Mendelsohn FAO (eds). *Membranes and receptors.* Elsevier 1984;237-244.
7. Vajda FJE. *Parameters of failed medical treatment in complex partial seizures.* In: Vajda FJE, Donnan GA (eds). *Refractory epilepsy.* York Press 1984;45-51.
8. Vajda FJE. *Anticonvulsant strategies in epilepsy. Pharmacological treatment of epilepsy* In: Vajda FJE, Donnan GA (eds). *Anti-convulsant strategies.* York Press 1984;101-109.
9. Vajda FJE *Anticonvulsant drugs: an overview.* Chapter 8, In: *Antimaniacs, anticonvulsants and other drugs in psychiatry , Drugs in Psychiatry Vol 4.* Elsevier Amsterdam, New York and Oxford 1987, pp161-188
10. Vajda FJE. *Role of conventional anticoagulant therapy.* In: Donnan GA, Vajda FJE (eds). *Problem areas in acute stroke management.* York Press (Melbourne) 1985;87-92.

11. Vajda FJE *Pentoxifylline (Trental)*. In: Donnan GA, Vajda FJE (eds). Problem areas in acute stroke management. York Press (Melbourne) 1985;92-96.
12. Vajda FJE. *Benzodiazepines past, present and future*. In: Vajda FJE, Donnan GA (eds). Grey areas in epilepsy. York Press (Melbourne) 1986;61-67.
13. Vajda FJE. *Management of advanced Parkinson's disease in the elderly*. In: Prinsley DM, Warne RW (eds). A manual of geriatric care. Williams and Wilkins, Baltimore 1988;306-323.
14. Vajda FJE. *Pharmacological aspects of antiepileptic therapy*. Proc Res Seminars, Queen Elizabeth Hospital Adelaide pp. 7-10.
15. Vajda FJE. *Practical approach to anticonvulsant monitoring*. Anticonvulsant Therapy. Buchanan N. (ed). Westmead Hospital Publication 1988;27-29.
16. Vajda FJE, Rowe CC, Berkovic SF. *Recent anticonvulsant studies; Promises unfulfilled*. Chapter 18, In: Focus on Epilepsy. Epilepsy Society of Australia publication Melbourne 1988 pp. 105-111.
17. Vajda FJE. *Disorders of sleep* Chapter 4 In: Drug Therapy in Neurology , MJ Eadie (Ed), Churchill Livingstone, Edinburgh and London, 1992, pp.73-84
18. Vajda FJE. *Disorders of the intellect- dementia*. Chapter 5 In: Drug Therapy in Neurology , MJ Eadie (Ed), Churchill Livingstone, Edinburgh and London, 1992, pp. 85-95.
19. Vajda FJE. *Upper Motor Neuron Disorders – spasticity*. Chapter 5 In: Drug Therapy in Neurology , MJ Eadie (Ed), Churchill Livingstone, Edinburgh and London, 1992, pp.173-180.
20. Vajda FJE. *Gabapentin*. Chapter 16, in: Handbook of Experimental Pharmacology Volume 138. Antiepileptic Drugs Pharmacology and Therapeutics. Eadie MJ, Vajda FJ (eds). Springer-Verlag, Berlin, Heidelberg, New York 1999; pp 425-446.
21. Eadie MF, Vajda FJE. *Older Anticonvulsants Continuing in Use but with Limited Advance in Knowledge*. Chapter 8, In: Handbook of Experimental Pharmacology Volume 138. Antiepileptic Drugs Pharmacology and Therapeutics. Eadie MJ, Vajda FJ (eds). Springer-Verlag, Berlin, Heidelberg, New York 1999; pp.189-229.
22. Dickinson RG, Eadie MJ, Vajda FJE. *Carbamazepine*. Chapter 10, In: Handbook of Experimental Pharmacology Volume 138. Antiepileptic Drugs Pharmacology and Therapeutics. Eadie MJ, Vajda FJ (eds). Springer-Verlag, Berlin, Heidelberg, New York 1999; pp.276-318.
23. Vajda FJE. *Gabapentin: Chemistry, Clinical Pharmacokinetics metabolism and Drug Interactions*. Chapter 30. In: Antiepileptic Drugs. Levy R, Meldrum B, Mattson R, Perucca E (eds). Lippincott, New York 2000, pp.335-339

24. Vajda FJE. Legal Considerations which impact upon the development of new therapeutic agents from the clinician's perspective. In: *Epilepsy and the Law of Therapeutics*, Beran RG (Ed) (2001). The International Center for Health, Law and Ethics (2004) pp 27-41
- 25 Vajda FJE, Chapter 27, Neuroprotection and Neurodegenerative Disease  
In: *Alzheimer's Disease- A Physician's Guide to Practical management*  
Richter RW and Zoeller Richter B (Eds)  
Humana Press , Totowa New Jersey, 2004 , pp 235-244
- 26 Vajda FJE and Solinas  
Porphyria, Epidemiology, Clinical Aspects and Management  
Chapter in *Intrnational Textbook of Neurology* W.Truong and W Carroll, (Eds)  
Blackwell 2010
27. PANAYIOTOPOLOUS ADD
- 28Chapter 1O, Brien TJ et al Editors
- 29Chapter 2 O,Brien TJ Editors
- 30 Vajda FJE and Eadie MJ ( by invitation)  
ILEA: website : Antiepileptic drugs  
Traditional AEDs

### c. ARTICLES :

1. Vajda FJE, Martin TJ, Melick RA. Destruction of bovine parathyroid labelled with 131I by rat kidney tissues. *Endocrinol* 1969;84:162-164.
2. Collaborative Group. Phenytoin after recovery from myocardial infarction. *Lancet* 1970;2:295-296.
3. Vajda FJE. Value of plasma phenytoin levels in the treatment of epilepsy. *Med J Aust* 1970;2:1074-1076.
4. Vajda FJE, Prineas RJ, Lovell RRH. Interaction between phenytoin and the benzodiazepines. *Brit Med J* 1971;1:346-347.
5. Lovell RRH, Prineas RJ, Vajda FJE. Long-term prognostic significance to ventricular extrasystoles in myocardial infarction. *Lancet* 1972;2:822-823.
6. Vajda FJE, Lovell RRH, Prineas RJ. Epileptics on phenytoin. *Brit Med J* 1972;2:295-296.

7. Vajda FJE. Poisoning and drug induced disease - physical agents. *Medicine* 1972;4:328-330.
8. Vajda FJE, Prineas RJ, Lovell RRH, Sloman JG. The possible effect of long-term plasma levels of phenytoin on mortality after acute myocardial infarction. *Eur J Clin Pharmacol* 1973;15:138-144.
9. Lovell RRH, Prineas RJ, Vajda FJE. Prophylactic use of antiarrhythmic drugs following myocardial infarction: Observation over twelve months. *Singapore Med J* 1974;14:211-213.
10. Silver J, Davies TJ, Kupersmitt E, Orme M, Petri A, Vajda FJE. The prevalence and treatment of vitamin D deficiency in children on anticonvulsant drugs. *Arch Dis Childhood* 1974;49:344-350.
11. Vajda FJE, Williams FM, Breckenridge AM, Davidson S, Falconer MA. Human brain, cerebrospinal fluid and plasma concentrations of diphenylhydantoin and phenobarbital. *Clin Pharm Therap* 1974;15:597-603.
12. Vajda FJE, Williams FM, Davies DS. Measurement of plasma concentrations of tolbutamide by simplified gas-liquid chromatography. *Med J Aust* 1974;1:64-65.
13. Vajda FJE. The measurement of plasma levels of antiepileptic drugs. *Aust Prescriber* 1975;1:6-7.
14. Vajda FJE, Merory J, Bladin PF. Fluctuations of plasma phenytoin levels on single dose and twice daily dose regimes. *Proc Aust Assoc Neurol* 1975;12:61-64.
15. Drummer O, Morris P, Vajda FJE. Plasma carbamazepine determinations: a simple gas chromatographic method. *Clin Exp Pharmacol Physiol* 1976;3:497-501.
16. LeQuesne P, Goldberg V, Vajda FJE. Acute conduction velocity changes in guinea-pigs after administration of diphenylhydantoin. *J Neurol Neurosurg Psych* 1976;10:95-100.
17. McNeil JJ, Vajda FJE, Louis WJ, Vijayasekaran V. Bioavailability comparison of two generic preparations of frusemide. *Med J Aust* 1977;2:505-506.
18. Mihaly G, Phillips J, Louis WJ, Vajda FJE. Measurement of carbamazepine and its epoxide in plasma: Comparison of assay techniques for measuring carbamazepine. *J Clin Chem* 1977;23:2283-2287.
19. Vajda FJE, Symington G, Bladin PH. Rectal valproate in intractable status epilepticus. *Lancet* 1977;i:359-360.
20. Bladin PF, Vajda FJE, Symington G. Therapeutic problems related to tonic status epilepticus. *Clin Exp Neurol* 1977;14:203-207.
21. Louis WJ, Christophidis N, Brignell M, Vijayasekaran V, McNeill JJ, Vajda FJE. Labetalol: Bioavailability, drug plasma levels, plasma renin and catecholamines in acute and chronic treatment of resistant hypertension. *Aust NZ J Med* 1978;8:602-609.
22. Vajda FJE, Mihaly G, Miles J, Morris P, Bladin PF. Sodium valproate: Dose-plasma level relationships and interdose fluctuations. *Proc Clin Exp Neurol* 1978;15:145-153.

23. Vajda FJE, Mihaly G, Miles J, Donnan G, Bladin PF. Rectal administration of sodium valproate in status epilepticus. *Neurology (Minneapolis)* 1978;28:897-898.
24. Christophidis N, Dawborn J, Vajda FJE. Studies in intravenous cefoxitin (MK 306). *Med J Aust* 1978;1:512-514.
25. Louis WJ, McNeil JJ, Brignell MJ, Christophidis N, Vajda FJE. Labetalol in hypertension. *Lancet* 1978;1:452-453.
26. Symington G, Leonard J, Shannon PJ, Vajda FJE. Sodium valproate in Huntington's chorea. *Am J Psychiat* 1978;135 3:353-354.
27. Vajda FJE, McNeil J, Morris P, Drummer O, Bladin PF. Sodium valproate in refractory epilepsy. *Aust NZ J Med* 1978;8:46-51.
28. Louis WJ, Vajda FJE, McNeil JJ, Doyle AE. The combines use of L- -mehyldopa hydrazine and methyldopa in the treatment of hypertension. *Clin Exp Pharm Physiol* 1978 4 (suppl):17-22.
29. Christophidis N, Lucas I, Vajda FJE, Louis WJ. Excessive lacrimation due to 5-fluorouracil. *Ann Inter Med* 1978;89 5:74.
30. Christophidis N, Vajda FJE, Lucas I, Drummer O, Moon WJ, Louis WJ. Fluorouracil therapy in patients with carcinoma of the large bowel: A pharmacokinetic comparison of various rates and routes of administration *Clin Pharmacokin* 1978;3:330-336.
31. Burrows GD, Norman TR, Vajda FJE. Benzodiazepines - Clinical applications. *Aust Press* 1978;1:167-170.
32. Vajda FJE, Donnan G, Bladin PF. Patterns of response to Levodopa in Parkinson's disease. *Clin Exp Neurol* 1978;15:299-306.
33. Louis WJ, McNeil JJ, Vajda FJE, Jarrott B. A double-blind cross-over comparison of panadol, metoprolol, atenolol and labetalol in mild to moderate hypertension. VII World Congress of Cardiology, Tokyo (Sept) 1978;17-23:471-475.
34. Christophidis N, Vajda FJE, Lucas I, Louis WJ. Ocular side effects of fluorouracil. *Aust NZ J Med* 1979;9-8.
35. Christophidis N, Vajda FJE, Lucas I, Moon WJ, Louis WJ. A comparison of intravenous and oral high dose methotrexate administration in treatment of solid tumours. *Brit Med J* 1979;1:298-300.
36. Christophidis N, Mihaly G, Vajda FJE, Louis WJ. Liquid and gas-liquid chromatographic assay of 5-fluorouracil in plasma: compared. *Clin Chem* 1979;25:83-87.
37. McNeil JJ, Louis WJ, Doyle AE, Vajda FJE. Comparison of metoprolol and pindolol in the treatment of mild to moderate hypertension. *Med J Aust* 1:431-433.
38. Mihaly G, Vajda FJE, Miles J, Louis WJ. Single and chronic dose pharmacokinetic studies of sodium valproate in epileptic patients. *Eur J Clin Pharmac* 1979;16:23-39.

39. Vajda FJE, Donnan GA, Mihaly G, Miles J, Bladin PF. Use of rectal sodium valproate in neurosurgical patients. *Neurol (Minneapolis)* 1979.
40. Mihaly GW, Miles JL, Louis WJ, Vajda FJE. Pharmacokinetic studies of sodium valproate at steady state in epileptic patients. *Eur J Pharmacol* 1979;16:23-29.
41. Lander C, Donnan G, Bladin PF, Vajda FJE. Some aspects of the clinical use of clonazepam in epilepsy. *Clin Exp Neurol* 1979;16:325-332.
42. Vajda FJE. Principles of pharmacology. *Aust Fam Phys* 1980;9:134-141.
43. Bladin PF, Vajda FJE. The brain in systemic hypertension: Current concepts in hypertension and cardiovascular disorders. *S Hunyor Ed* 1980;1:4-9.
44. Vajda FJE, Bladin PF, Miller BJ. The value of limitations of valproate in status epilepticus. *Aust J Hosp Pharmacy* 1981;11 No.1:10-12.
45. Vajda FJE. Another look at the management of epilepsy. *Aust Fam Phys* 1981;10:642-648.
46. Vajda FJE, Chambers B. Differentiation of organic and functional seizures. *Aust Fam Phy* 1981;10:960-965.
47. Vajda FJE. Administration of valproate and phenytoin. *Neurology* 1981;31-643.
48. Vajda FJE, Donnan GA, Phillips J, Bladin PF. Human brain, CSF and plasma valproate levels after 72 hours therapy. *Neurology (Minneapolis)* 1981;31:486-487.
49. Yeomans ND, Vajda FJE, Baldas J. Bioavailability of valproate after gastric and direct intestinal administration in rats. *Clin Exp Pharm Phys* 1981;9:173-177.
50. Vajda FJE, Proudfoot AD, Phillips J, Rozitis J. Use of an anticonvulsant plasma level monitoring service. *Aust J Hosp Pharm* 1981;11:103-107.
51. Christophidis N, Louis WJ, Lucas I, Moon W, Vajda FJE. Renal clearance of methotrexate in man during high-dose oral and intravenous infusion therapy. *Cancer Chemother Pharm* 1981;6:59-64.
52. Papanicolaou J, Vajda FJE, Summers RJ, Louis WJ. Role of beta adrenoceptors in the anticonvulsant effect of propranolol of pentylenetetrazol-induced convulsions in rats. *J Pharm Pharmac* 1982;34:124-125.
53. Louis WJ, Papanicolaou J, Summers RJ, Vajda FJE. Role of central beta adrenoceptors in the control of pentylenetetrazole induced convulsions in rats. *Brit J Pharm* 1982;75:441-446.
54. Papanicolaou J, Summers RJ, Vajda FJE, Louis WJ. Anticonvulsant effects of clonidine mediated through central alpha<sub>2</sub>-adrenoceptors. *Eur J Pharm* 1982;77:163-166.
55. Papanicolaou J, Summers RJ, Vajda FJE, Louis WJ. The relationship between alpha adrenoceptor selectivity and anticonvulsant effect in a series of clonidine-like drugs. *Brain Res* 1982;241:393-397.

56. Summers RJ, Papanicolaou J, Vajda FJE, Louis WJ. Enhancement of pentylenetetrazol induced convulsions in rats by central alpha2-adrenoceptor antagonism. *Neurosci Lett* 1982;8:583.
57. Yeomans ND, Vajda FJE, Baldas J. Bioavailability of valproate after gastric and direct intestinal administration in rats. *Clin Exp Pharm Therap* 1982;9:173-177.
58. Mihaly GW, Smallwood RA, Anderson JD, Jones DB, Webster LK, Vajda FJE. H<sub>2</sub>-receptor antagonists and hepatic drug disposition. *Hepatology* 1982;2(6):828-831.
59. Dreifuss FE, Vajda FJE, Spira PJ, Beran RG, O'Donohoe NV. Clinical focus on epilepsy. *Int Med Forum* 1982;4-5.
60. Papanicolaou J, Summers RJ, Vajda FJE, Louis WJ. The role of alpha2-adrenoceptors in potentiations of pentylenetetrazol-induced seizures by alpha-adrenoceptor antagonists in rats. *Eur J Pharmacol* 1982;77:163-166.
61. Vajda FJE, Aicardi J. Reassessment of the concept of a therapeutic range of anti-convulsant plasma levels. *Dev Med Child Neurol* 1983;25:660-671.
62. Vajda FJE, Burrows GW. Drugs in the treatment of anxiety. *Aust Fam Phys* 1983;12:714-717.
63. Vajda FJE. Drugs in Epilepsy. *Current Therap* 1983;24:127-141.
64. Vajda FJE, Bladin PF. Interaction between Erythromycin-base and carbamazepine. *Med J Aust* 1984;140:81.
65. Webster LK, Mihaly GW, Jones DB, Smallwood RA, Phillips JA, Vajda FJE. Effect of Cimetidine and Ranitidine on Carbamazepine and Sodium Valproate pharmacokinetics. *Eur J Clin Pharm* 1984;27:341-347.
66. Vajda FJE. Drug treatment of epilepsy. *Aust Family Physic* 1984;13:431-434.
67. Berkovic SF, Bladin PB, Connelly MD, Gassat LA, Bymington GR, Vajda FJE. Experience with continuous ambulatory EEG monitoring. *Clin Exp Neurol* 1984;20:37-46.
68. Vajda FJE, Woodward J, Donnan GA. Management of subarachnoid haemorrhage. *Aust J Hosp Pharm* 1986;16(2):95-100.
69. Donnan GA, Kaczmarczyk SJ, Solopotias T, Rowe P, Kalnins RM, Vajda FJE, Mendelsohn FAO. The neurochemical and clinical effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in small animals. *Clin Exp Neurol* 1986;22:155-164.
70. Harris QLG, Lewis SJ, Young NA, Vajda FJE, Jarrott B. Microcomputer analysis techniques for evaluation of benzodiazepine effects on rat electro-corticogram. *EEG Clin Neurophysiol* 1987;66(3):331-334.
71. Harris QLG, Lewis SJ, Young NA, Vajda FJE, Jarrott B. The relationship between the effects of diazepam and clobazam on electroencephalographic parameters and on kindled amygdaloid seizures in rats. *Clin. Exp. Pharmacol. Physiol.* 1988.15(10):753-764

72. Harris QLG, Lewis SJ, Shulkes A, Vajda FJE, Jarrott B. Regional brain concentrations of cholecystokinin in the rat: the effects of kindled and non-kindled seizures. *Neuropharmacology* 1988;27(5) 547-550
73. Shulkes A, Harris QLG, Lewis SJ, Vajda FJE, Jarrott B. Regional brain concentrations of neurotensin following amygdaloid kindled and cortical suprathreshold stimulation-induced seizures in the rat. *Neuropeptides* 1988 11(2):77-81.
74. Vajda FJE, Lewis SJ, Harris QLG, Jarrott B, Young NA. Tolerance to the anticonvulsant effects of clonazepam and clobazam in the amygdaloid kindled rat. In: *Clinical and Experimental Neurology*, 1986;22:155-164 Eds Tyrer JH, Eadie MJ. Adis Press.
75. Young NA, Lewis SJ, Harris QL, Jarrott B and Vajda FJE Chronic benzodiazepine administration and in vitro binding to cortical synaptosomal fraction *Epilepsia* 1988. 30: 458-463 ok
76. Young NA Lewis SJ Harris QL, Jarrott B and Vajda FJE  
The development of tolerance to the anticonvulsant effects of clonazepam but not sodium valproate in the amygdaloid kindled rat *Neuropharmacology* 26; 1611 1987
77. Vajda FJE. Conselling patients with migraine. *Aust Pharmac* 1987;6:30-32.
78. Jarrott B, Vajda FJE. Status of monoamine oxidase inhibitors in Parkinson's disease. *Med J Aust* 1987;146:634-638.
79. Vajda FJE. Current anticonvulsant therapy. *Mod Med* 1987;Supplement:20-30.
80. Vajda FJE. A practical approach to therapeutic drug monitoring. In: Buchanan N (ed). *Epilepsy. A Symposium*, Ciba Geigy Australia 1988.
81. Vajda FJE, Drummer O, Morris PM, McNeil JJ, Bladin PF. Gas chromatographic measurement of plasma levels of sodium valproate: tentative therapeutic range of a new anticonvulsant in the treatment of refractory epileptics. *Clin Exp Pharmacol Physiol* 1988;5:67-73.
82. Young NA, Lewis SJ, Harris QLG, Jarrott B, Vajda FJE. Differences in the development of tolerance to two anticonvulsant benzodiazepines in the amygdaloid kindled rat. *J Pharm Pharmac* 1988;40:365-367
83. Vajda FJE. New Anticonvulsants *Current Science - Current opinion. Neurology and Neurosurgery* 1992;519 519-525.
84. Schapel GJ, Beran RG, Vajda FJE, Berkovic SF, Mashford ML, Dunagan FM, Yuen WC, Davies G. Double-blind placebo controlled crossover study of lamotrigine in treatment resistant partial seizures *J Neurol Neurosurg and Psych* 1993;56:448-453.



85. Anhut H, Ashman P, Feuerskin TJ, Saurmann W, Saunders M, Schmidt B. and the International Gabapentin Study Group. Gabapentin (Neurontin) as Add-on Therapy in Patients with partial seizures: A Double-Blind, Placebo-Controlled Study. *Epilepsia* 35:(4)795-801 1994.
86. Collaborative Group. A double-blind, placebo controlled crossover study of vigabatrin 2g/day and 3.3g/day in uncontrolled partial seizures. *Seizure* 5:259-265 (1996).
87. Vajda FJE. Monitoring of Antiepileptic Therapy. Inaugural Australian Merritt and Putnam Lecture. *Epilepsy Society of Australia Annual Scientific Meeting* , 1997
88. Angelis P, Vajda FJE, Christophidis N. Effects of non-steroid anti-inflammatory drugs (NSAIDs) on human polymorphonuclear leucocytes in buffer and plasma. *Clin Exp Rheumatol* 1998;16:703-708.
89. Vajda FJE. Topiramate a novel antiepileptic drug. *Medical Observer Journal*, Manila, Philippines. Accepted for publication November 1998.
90. Vajda FJE. Selegiline: Its role in treatment of Parkinson's Disease. *Parkinson Australia*, Perth, Proceedings pp. (Oct 1998).
91. Salzberg M, Vajda FJE. Epilepsy, depression and antidepressant drugs *J Clin Neurosciences* (2001);8(3):209-215
93. Beran RG, Berkovic SF, Dunagan FM, Vajda FJE, Danta G, Black AB and Mackenzie R. A Double-Blind, Placebo-Controlled, Crossover Study of Lamotrigine in Treatment-Resistant Generalised Epilepsy. *Epilepsia* 39 (2) 1329-1333 1998
94. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind placebo controlled trial of diclofenac/misoprostol in Alzheimer's disease. *Neurology* 1999; 53:19-201.
95. Angelis-Stoforidis P, Vajda F, Christophidis N. Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. *Clin Exp Rheumatology* 1999;17(3)313-320
96. Vajda FJE. Antiepileptic Drug Withdrawal. Can Response Be Predicted? *Current Therap* 34:17-21 1993.
97. Angelis P, Scharf S, Mander A, Vajda F, Christophidis N. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer's disease. *Neuroscience Letters* 1998; 244:106-108.
98. Angelis P, Morgan D, Vajda FJE. Determination of lamotrigine in human plasma by high performance liquid chromatography. *J. Chromatography B*. 727(1999) 113-118.
99. O'Brien TJ, Vajda FJE. Contemporary management of epilepsy in pregnancy based on currently available information  
*Austr. NZ J Obstet and Gynaecol* (2000)(40):413-415
100. Vajda FJE. The Management of Epilepsy in Pregnancy. *Current Therapeutics*. August 2000, 41:27-31

- 101 Vajda FJE, Tomson T, Perucca E. The Ethics of Pregnancy Registries. Submitted in Epilepsia. November 2000.
- 102 Beghi E, Annegers JF for the Collaborative Group (Battino D, Montouris G, Morrell M, Morrow J, Perucca E, Thomas SV, Tennis P, Tomson T, Vajda F, Yerby M. Pregnancy Registries in Epilepsy. Epilepsia. Submitted November 2000.
- 103 Vajda FJE: New Antiepileptic Drugs. Journal of the Clinical Neurosciences (2000) 7(2) 88-101.
- 104 Tomson T, Battino D, Beusart M, Brodie MJ, Craig J, Lindhout D, Mormoli D, Ried J, Sabers A, Schmidt B, Perucca E and Vajda FJE: A European Registry of anti-epileptic drugs and pregnancy EURAP: Aims, Methods and Organisation, Epilepsia, Oct 2000.
- 105 Ettore, Beghi E, and Annegers JF for the Collaborative group (Battino D, Montouris G, Dumas C, Morrell M, Morrow J Perucca E, Thomas SV, tennis P, Tomson T, Vajda FJE and Yerby F): Pregnancy Registries in Epilepsy, Epilepsia, Dec 2000 (submitted for publication).
- 103 Tomson T, Battino D, Bonizzoni E, Carig J, Lindhout D, Perucca E, Sabers A and Vajda FJE Antiepileptic Drug Registries, Epilepsia 2004 . 45(11) 1463-4)
- 104 Vajda FJE Plasma monitoring of Antiepileptic drugs –changed perspectives Current Therapeutics, 2001;42,(9;9-13
- 105 O'Brien TJ, Meara F, Matthews H and Vajda FJE : A prospective study of local cutaneous reactions in patients receiving intravenous phenytoin Neurology 2001. 57:158-160
- 106 O'Brien TJ and Vajda FJE Letter to the Editor: correspondence on the local cutaneous reaction purple limb syndrome in patients receiving intravenous phenytoin Neurology 14.Nov.2001
- 107 Vajda FJE Neuroprotection and Neurodegenerative Disorders J. Clin. Neurosci. (2002) 9;(1): 4-8
108. S F Berkovic and FJE Vajda Generics, equal or not ? Australian Prescriber 26.(6), 2003 :124-5
- 109 Vajda FJE and Eadie MJ Maternal valproate dosage and foetal malformations Acta NeurolScandinavica ,( 2005), ( 2005), 112:137-143 ,
110. Vajda FJ, O'Brien TJ, Hitchcock A, Graham J, Cook M, Lander CM and Eadie MJ Critical relationship between sodium valproate dose and human teratogenicity: results of the Australian register of antiepileptic drugs in pregnancy J Clin Neuroscience 2004; 11(8), 854-858
111. Vajda FJE.

The Management of Epilepsy in Pregnancy. Editorial comment  
Current Therapeutics. August 2000, 41:27-31

112 Vajda F, O'Brien T, Hitchcock A, Graham J, Lander C.  
The Australian Registry of Anti-epileptic drugs in Pregnancy: experience after 30 months.  
J Clin Neurosci 2003;10:543-549.

113 EURAP

Tomson T, Perucca E, Battino D, Lindhout D, Sabers, and Vajda FJE  
EURAP report on seizure related observations from the European Register of Antiepileptic  
drugs in Pregnancy  
Epilepsia 2005, ON LINE BEFOREPRINT 28DEC. 2005  
NEUROLOGY 2006;66:354-360

114

Five Year report of the Australian Pregnancy Registry for Women on Antiepileptic Medication.

Vajda, F<sup>1,2</sup>, Lander, C<sup>4</sup>, Hitchcock, A<sup>1</sup>, Graham, J<sup>1</sup>, Solinas, C<sup>1</sup>, O'Brien, T<sup>3</sup>, Reutens, D<sup>2</sup>, Eadie, M<sup>4</sup>  
World Congress of Neurology, Sydney, Nov. 2005

116 Vajda FJE and SF Berkovic  
Switchability of antiepileptic drugs  
Australian Journal of Pharmacy  
2005;86:598

117 FJE Vajda

Epilepsy and Pregnancy - Emergence of Pregnancy Registries.  
By invitation  
The Medical Observer, Hong Kong, 2006,;33(2);74-81

118 F. Vajda, C. Solinas

Current approaches to management of depression and Parkinson's Disease,  
J Clin Neurosci, 2005, 12(7):739-743

119 Vajda FJE

Vajda FJE, Lander ML, Graham J, Hitchcock C, Solinas C, O'Brien TJ and Eadie MJ  
The case for lamotrigine monitoring in pregnancy.  
J. Clin. Neurosciences 13(2006):1

120 FJE Vajda

A case for NEUROSCIENCE TRIALS AUSTRALIA  
J. Clin Neurosciences 12(2006):168-171

121 Vajda FJE,

Manuscript No 2004/40  
Title Potential risks associated with high dose valproate in pregnancy in psychiatric patients  
Aust NZ J Psychiatry 2005;39(6):526-527

122.C. Solinas and FJE Vajda

Epilepsy and Porphyria:  
New Perspectives  
Journal of Clinical Neuroscience  
(2004),11(356-361)

123 Vajda FJE

Sudden Unexpected Death In epilepsy

Journal of Clin.Neuroscience, (2004) 12;2:210

106 Tomson T, Battino D, Beusart M, Brodie MJ, Craig J, Lindhout D, Mormoli D, Ried J, Sabers A, Schmidt B, Perucca E and Vajda FJE: A European Registry of anti-epileptic drugs and pregnancy EURAP: Aims, Methods and Organisation, Epilepsia, Oct 2000.

125. Spira P and Beran R and the Australian Chronic Daily Headache Group

Gabapentin in the prophylaxis of chronic daily headache: a randomized, placebo controlled study

Neurology 61: 1752-1759 (2003)

126. Frank J E Vajda, Terrence O'Brien, Alison Hitchcock, Janet Graham, Cecilie Lander and Mervyn Eadie

THE INTERNAL CONTROL GROUP IN A PREGNANCY - ANTIEPILEPTIC DRUG REGISTER

J Clin Neurosci 19 Nov 2007, ( E pub ahead of print)

127 Frank J E Vajda, Terence O'Brien, Alison Hitchcock, Janet Graham, Cecilie Lander and Mervyn Eadie

AUSTRALIAN PREGNANCY REGISTER OF ANTIEPILEPTIC DRUGS – ASPECTS OF DATA COLLECTION AND ANALYSIS

J.Clin. Neuroscience 2006 2007;14;936-942

128. Frank J E Vajda, Terence O'Brien, Alison Hitchcock, Janet Graham, Cecilie Lander and Mervyn Eadie

THE DOSE-DEPENDENCE OF ANTIEPILEPTIC DRUG RELATED FOETAL MALFORMATIONS

Submitted for publication J.Neurol.Neurosurg. Psych. May 2006

129 Frank J E Vajda, Terence O'Brien, Janet Graham, Alison Hitchcock, Cecilie Lander and Mervyn Eadie

PREGNANCIES IN WOMEN WITH EPILEPSY

2006; ,J.Roy.Coll.Phys.Edin. 36:201-207

130. FJE Vajda

Pharmacotherapy of Epilepsy,

J.Clin. Neuroscience 2007 ;14(9)813-823

131. Vajda FJE, Lander CM, Hitchcock A , Graham J, O'Brien TJ and Eadie MJ. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry

*European Journal of Neurology.* 2005;13(6):645-65

132 Beran R., Berkovic DS, Black AB Danta G, Hiersemenzel R, Schapel G, and Vajda FJE

Efficacy and safety of Levetirecetam 1000-3000 mg/day in patients with refractory partial onset seizures – a multicentre open label single arm study Report of Clinical trial in partial Epilepsy  
Epi. Research 2005,63:1-9

133

Neurological complications of porphyria; presentation of 14 patients

C. Solinas, F. Vajda

submitted J. Clin. Neurooscience

May 2006.

Accepted for publication, Jan 2007-10-24

134. FJE Vajda

Monitoring antiepileptic drug therapy with serum level measurements

Editorial Comment

By invitation, Medical Journal of Australia.

2007;187(10) 581

135 The EURAP STUY GROUP

Craig J, Prerucca E, Sobers A, Tomson T, Vajda F, H Bonizoni, Battino D and Lindhout D

Seizure control in antiepileptic drug-treated pregnancy

Neurology 2006 ;66:354-360

136. Vajda FJE, Lander CM, Hitchcock A , Graham J, O'Brien TJ and Eadie MJ.

Seizure control on antiepileptic drug treated pregnancy

Accepted for publication Epilepsia , NY September 2, 2007

In 21.Nov 2007 Published as e-print before publication

137 Vajda FJE, Lander CM, Hitchcock A , Graham J, O'Brien TJ and Eadie MJ.

Outcome Report after 1002 The Australian Register of AEDs I pregnancy: the first 1002 pregnancies

Austr NZ J Obs and Gynae 2007;47: 468-474

138 Vajda FJE, O'Brien TJ, Hitchcock A, Graham J , Lander CM and Eadie MJ

Dose dependence of antiepileptic drug associated foetal malformations

J Clin. Neurosci 2007 ; 14:1036 Oct 2007

139 Tomson T, Battino D, French J, Harden C, Holmes C, Morrow J, Robert-Gnansia E, Scheurle A, Vajda F, and Gordon J

Antiepileptic drug exposure and major congenital malformations: the role of pregnancy registries

Epilepsy Behav 2007 Nov, ;11(3):277-282

140. Vajda FJE

Management of pregnancy in women with epilepsy

Expert Report on Pharmacotherapy By invitation

Submitted, March 2008

141 Vajda FJE, Lander CM, Hitchcock A , Graham J, O'Brien TJ and Eadie MJ

Internal control of the Australian Register of Pregnancies

J.Clin Neurosci. January 2008

142 Solinas C and Vajda FJE

Neurological complications of Porph  
 J.Clin Neuroscience , Pub Med edition  
 Feb.2008, 18187328 Biol.Info Bank Library

143. Vajda FJE, Lander CM, Hitchcock A , Graham J, O'Brien TJ and Eadie MJ.  
 Patterns of prescribing of antiepileptic drugs and effects  
 To be submitted J.Clin Neurosciences, March 2008

144. Vajda FJE, Lander CM, Hitchcock A , Graham J, O'Brien TJ and Eadie MJ.  
 Relative risk associated with treatment of WWE in pregnancy  
 In preparation. To be submitted to Lancet ( Neurology) April 2008

145 Vajda FJE  
 Treatment options for pregnant women with epilepsy  
 Expert Opin. Pharmacother. (2008) 9(1):1-10 ( by invitation)

146 FJE Vajda, CM Lander TJ O'Brien MJ Eadie AO  
 Why have Pregnancy Registers ? An explanation. Editorial  
 By invitation Med. J Australia  
 Submitted Dec.5.2010

147Vajda FJE  
 Treatment options for pregnant women with epilepsy  
 Expert Opin Pharmacother  
 2008 Aug : 9, (11) 1859-68 .

148Tomson T, Battino D, Beusart M, Brodie MJ, Craig J, Lindhout D, Mormoli D, Ried J,  
 Sabers A, Schmidt B, Perucca E and Vajda FJE: A European Registry of anti-epileptic drugs and  
 pregnancy EURAP: Aims, Methods and Organisation, Epilepsia, Oct 2000.

149Vajda 112 Vajda F, O'Brien T, Hitchcock A, Graham J, Lander C.  
 The Australian Registry of Anti-epileptic drugs in Pregnancy: experience after 30 months.  
 J Clin Neurosci 2003;10:543-549

150Vajda FJE, Hollingworth S, Graham AA , Hitchcock AA, O'Brien TJ , Lander CM and Eadie  
 MJ, AO.  
 Changing patterns of antiepileptic drug use in pregnant Australian women  
 Acta Neurol Scand 2009, 121;(2): 89-93

Vajda F O'Brien T, Hitchcock A, Graham J, Lander C and Eadie M  
 The internal control group in a register of antiepileptic drug use in pregnancy  
 J Clin Neurosci 2008: 15: (1) :29-35

152 Vajda FJ, Hitchcock AA, Graham J, O'Brien TJ, Lander CM, and Eadie MJ  
The teratogenic risk of antiepileptic drug polytherapy  
Epilepsia 2009; 51(5) 805-810

153 [The rationale for pregnancy registers for women with epilepsy.](#)

Vajda FJ, O'Brien TJ, Lander CM, Eadie MJ.

Med J Aust. 2011 Jul 4;195(1):8-9.

154 [Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry.](#)

Tomson T, Battino D, Bonizzoni E, Craig J, Lindhout D, Sabers A, Perucca E, **Vajda F**; for the EURAP study group.

Lancet Neurol. 2011 Jul;10(7):609-617. Epub 2011 Jun 5.

155 [Language skills of school-aged children prenatally exposed to antiepileptic drugs.](#)

Nadebaum C, Anderson VA, **Vajda F**, Reutens DC, Barton S, Wood AG.

Neurology. 2011 Feb 22;76(8):719-26.

156 [The Australian brain and cognition and antiepileptic drugs study: IQ in school-aged children exposed to sodium valproate and polytherapy.](#)

Nadebaum C, Anderson V, **Vajda F**, Reutens D, Barton S, Wood A.

J Int Neuropsychol Soc. 2011 Jan;17(1):133-42. Epub 2010 Nov 19.

157 [Valproic acid use in pregnancy and congenital malformations.](#)

**Vajda F**, O'Brien T.

N Engl J Med. 2010 Oct 28;363(18):1771-1772.

158 [Foetal malformations after exposure to antiepileptic drugs in utero assessed at birth and 12 months later: observations from the Australian pregnancy register.](#)

Vajda FJ, Graham J, Hitchcock AA, O'Brien TJ, Lander CM, Eadie MJ.

Acta Neurol Scand. 2011 Jul;124(1):9-12. doi: 10.1111/j.1600-

159 [The Australian Pregnancy Register of Anti-epileptic Drugs: 10](#)

[years of progress.](#)

Vajda FJ.

J Clin Neurosci. 2010 Dec;17(12):1485-8. Epub 2010 Sep 9. Review.

160 [Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register.](#)

Vajda FJ, Graham JE, Hitchcock AA, O'Brien TJ, Lander CM, Eadie MJ.

Seizure. 2010 Nov;19(9):558-61. Epub 2010 Aug 24.

161 [Changing patterns of antiepileptic drug use in pregnant Australian women.](#)

Vajda FJ, Hollingworth S, Graham J, Hitchcock AA, O'Brien TJ, Lander CM, Eadie MJ.

Acta Neurol Scand. 2010 Feb;121(2):89-93. Epub 2009 Dec 15.

162 [The teratogenic risk of antiepileptic drug polytherapy.](#)

Vajda FJ, Hitchcock AA, Graham J, O'Brien TJ, Lander CM, Eadie MJ.

Epilepsia. 2010 May;51(5):805-810

163FJE VAJDA

INTRAVENOUS VPA AND LEV

J CLIN NEUROSCIENCE

164Vajda FJE and O'Brien TJ

Valproic Acid Use in Pregnancy and Congenital Malformations

New Engl. J Med 2011 362: 1771-2

165Vajda FJE

The Australian Pregnancy Register of Anti-epileptic Drugs: 10 years of progress.

Clin Neurosci. 2010 Dec;17(12):1485-8..

166F Vajda, HORGAN D, HOLLINWORTH S J Graham, A Roten, C Lander, T O'Brien & M Eadie AO

The prescribing of antiepileptic drugs for pregnant Australian women  
AUSTR. NZ J.OBSTETICS AND GYNAE,



Published  
Sept 12 2011.

167Vaj FJ O'Brien TJ Lander CM Graham JJ Roten A and Eadie MJ  
Teratogenicity of the Second Generation of Antiepileptic Drugs  
J Neuroscience 2012

168 Vajda FJE  
Dose Issues in Epilepsy  
Submitted J. Clin Neuroscience  
Feb 2012

169 Vajda FJE , Dodd S and Horgan D  
Lamotrigine – a drug for all seasons  
Submitted J Clin neuroscience  
Feb 2012

170 167Vaj FJ O'Brien TJ Lander CM Graham JJ Roten A and Eadie MJ  
Repeted Pregnancies in Pregnant women with epilepsy  
Submitted to  
Epilepsia  
Feb 2012

171Schapel G, Beran RA, Vajda FJE et al  
Lamotrigine in Partial epilepsy

172 tomson\* battino epilepsia

173 Keppra 1APER BERAN ADD

174

ADD REVIEW PAPER BY NADEBAUM ADD

175dd Autism

176Add language

177Add IQ

178Utilization of Antiepileptic Drugs during Pregnancy: Comparative Patterns in 38 Countries Based on Data from the EURAP Registry” has accepted for publication Epilepsia under the authorship of “The EURAP Study Group.”

32 Teratogenicity of the newer antiepileptic drugs – The Australian experience

4 F.J.E. Vajda [a,b,↑](#), J. Graham [c](#), A. Roten [c](#), C.M. Lander [d,e](#),  
T.J. O'Brien [a](#), M. Eadie

[Volume 19, Issue 1](#) , Pages 57-59, January 2012

D. Abstracts: THESE ARE TO BE ADDED TO, ABOUT 60 more ACTS

1. Martin TJ, Vajda FJE, DeLuise M, Mellik RA. *A kidney microsomal enzyme for destruction of parathyroid hormone.* Med J Aust 1968;2:7421.
2. Vajda FJE, Lovell RRH, Prineas RJ, Sloman JG. *Diphenylhydantoin blood levels in patients on long-term oral treatment of the prophylaxis of cardiac arrhythmias.* Aust Soc Clin Exp Pharmacol 1969;4:15.
3. Vajda FJE, Fennessy MR. *Phenytoin tolerance tests: Individual variation in plasma levels as a result of differences in hepatic microsomal enzyme activity.* Aust Soc Clin Exp Pharmacol 1971;27.
4. Slowman GJ, Urquart C, Connor L, Vajda FJE. *The effect of dilantin on the systolic time intervals of the cardiac cycle.* Proc Aust Soc Med Res 1971;2:131.
5. Vajda FJE. *Pharmacology of drugs used in the treatment of Parkinson's disease.* Pharmaceutical Society Symposium, Melbourne 1975.
6. Vajda FJE, Morris PH. *Patterns of changes in plasma levels of valproate and phenytoin in patients on multiple anticonvulsant therapy.* Aust Soc Clin Exp Pharmacol, Proc Adelaide 1976.
7. Bladin PF, Vajda FJE. *Experience with sodium valproate.* Epilepsy in the Community. International Symposium Adelaide, Nov 26-28, 1976.

8. Vajda FJE. *The place of plasma drug assays in medical treatment*. Royal Australian College of Pathologists Annual Meeting, Melbourne 1977;16.
9. Louis WJ, McNeil JJ, Vajda FJE. *A double-blind cross-over comparison of atenolol, labetalol, metoprolol and pindolol in hypertension*. *International Symposium: Atenolol in Hypertension*, Melbourne and Sydney 1977.
10. Mihaly G, Phillips J, Vajda FJE. *The measurement of carbazepine and its metabolite by high pressure liquid chromatography in epileptic patients*. *Clin Exp Pharmacol* Sydney 1978;78.
11. Mihaly GW, Miles J, Louis WJ, Vajda FJE. *Pharmacokinetic studies of sodium valproate following acute and chronic administration in epileptic patients*. *Aust Soc Clin Exp Pharmacol*, Melbourne 1978.
12. Christophidis N, Vajda FJE, Lucas I, Moon WJ, Louis WJ. *A comparison of IV and oral high dose methotrexate (HD-MTX) in the treatment of solid tumours*. *Aust Soc Clin Exp Pharmacol*, Melbourne 1978.
13. Christophidis N, Mihaly G, Vajda FJE, Louis WJ. *A sensitive HPLC assay for 5-fluorouracil (5FU): A Comparison with GLC*. *Aust Soc Clin Exp Pharmacol Annual meeting - Christchurch NZ*, 1978.
14. Vajda FJE. *Recent advances in neurology*: Postgraduate Committee and RACP. *Management of Epilepsy*, RMH Melbourne 1978;12.
15. Vajda FJE, Lovell RRH, Prineas RJ, Sloman JG. *Phenytoin (diphenylhydantoin) blood levels in attempted arrhythmia prophylaxis*. *Cardiovas Res VI World Congress in Cardiology*, BMA London 1979;315.
16. Christophidis N, Vajda FJ, Lucas I, Louis WJ. *Ocular side effects with 5-fluorouracil*. *Aust & NZ Journ of Med*, 1979;9(2):143-144.
17. Christophidis N, Vajda FJE, Lucas I, Drummer O, Louis WJ, Moon WJ. *Excessive lacrimation of fluorouracil therapy with detectable concentrations of 5-FU in tears and plasma*. *Clin Exp Pharmacol Physiol* 1979;6:193-194.
18. McQueen AE, Singer G, Vajda FJE, Louis WJ. *Effects of parachlorophenylalanine and alpha-methylparatyrosine on social dominance and cerebral amine concentrations in rats*. *First joint meeting of the Aust Physiol Pharmacol Soc and Aust Soc Clin Exp Pharmacol*, Sydney 1979;173.
19. Christophidis N, Vajda FJE, Lucas I, Moon WJ, Louis WJ. *Ocular side-effects with 5-fluorouracil*. *J Am Med Assoc* 1979;242-475.
20. Lucas I Christophidis N, Vajda FJE, Moon WJ, Louis WJ. *Bioavailability of fluorouracil capsules*. *First joint meeting of the Aust Physiol Pharmacol Soc and Aust Soc Clin Exp Pharmacol*, Sydney 1979;325.
21. Christophidis N, Vajda FJE, Lucas I, Moon WJ, Louis WJ. *Renal clearance of emthotrexate (CMTX) in man during high dose oral and infusion therapy*. *First joint meeting of the Aust Physiol Pharmacol Soc and Aust Soc Clin Exp Pharmacol*, Sydney 1979;326.

22. Christophidis N, Vajda FJE, Lucas I, Moon WJ, Louis WJ. *Comparison of intravenous and oral high-dose methotrexate in the treatment of solid tumours.* Therap Drug Mon 1979;1,1:137.
23. Vajda FJE, Christophidis N, Lucas I, Moon WJ, Louis WJ. *Renal clearance of methotrexate in man during high dose oral and intravenous infusion.* Internat Soc Oncol, Nice, France 1979;184.
24. Lucas I, Vajda FJE, Moon WJ, Louis WJ. *Pharmacokinetic studies of cis platinum.* Clin Oncol Soc Aust 1979.
25. Christophidis N, Dawborn J, Vajda FJE. *Studies of intravenous cefoxitin.* Proc World Congress of Gynaecology, Tokyo 1979;25.
26. Vajda FJE. *Treatment of epilepsy in adults: Application of pharmacokinetic principles.* Royal Australasian College of Surgeons and Royal College of Physicians and Surgeons of Canada, combines meeting, by invitation Sydney 1980;183.
27. Louis WJ, Lucas I, Moon WJ, Vajda FJE. *Pharmacokinetics of cisplatin in man.* Proc World Conference on Clinical Pharmacology and Therapeutics 1980;7:687.
28. Papanicolaou J, Vajda FJE, Louis WJ. *Anticonvulsant activity of propranolol.* Proc World Conference of Clinical Pharmacology and Therapeutics 1980;236.
29. Mihaly GW, Vajda FJE. *Carbamazepine monotherapy in epileptic patients.* Clin Exp Pharmac Physiol 1980;7:650.
30. Vajda FJE, Marshall AW, Mihaly GW, Smallwood RA, Baldas J, Phillips J. *Hepatic elimination of sodium valproate.* Clin Exp Pharmacol Physiol 1980;7:673.
31. Yeomans ND, Vajda FJE, Baldas J. *Gastric absorption of valproate in rats.* Clin Exp Pharmacol Physiol 1980;7.
32. Papanicolaou J, Vajda FJE, Louis WJ. *Anticonvulsant activity of propranolol.* Clin Exp Pharmacol Physiol 1980;7:687.
33. Vajda FJE, Donnan GA, Phillips J, Bladin PF. *Brain, CSF and plasma valproate in man.* Clin Exp Neurol 1980;5.
34. Chambers B, Vajda FJE. *The role of stress and factors in the diagnosis of epilepsy.* Clin Exp Neurol (accepted) April 1980.
35. Marshall AW, Mihaly GW, Smallwood RA, Baldas J, Phillips J, Vajda FJE. *Hepatic elimination of the anti-epileptic agent sodium valproate.* Amer Assoc for the Study of Liver Disease, Salt Lake City, Utah (May) 1980.
36. Lucas I, Vajda FJE, Francis G, Drummer O, Louis WJ, Moon WJ. *Pharmacokinetics of cisplatin following intravenous administration.* National Cancer Institute Seminar, Bethesda Med USA May 1980.
37. Lucas I, Louis WJ, Moon WJ, Vajda FJE. *Studies of cisplatin in cancer patients following three courses of intravenous infusion.* Aust Soc Clin Exper Pharmacol, Canberra Dec 1980.

38. Mihaly GW, Smallwood RA, Jones DB, Vajda FJE. *H2 receptor antagonists and hepatic drug disposition*. Proc Aust Soc Clin Exp Pharmacol 1980.
39. Papanicolaou J, Vajda FJE, Louis WJ. *Comparison of the effect of four different beta-adrenoceptor blockers on pentylenetetrazol-induced seizures*. Aust Soc Clin Exper Pharmacol, Canberra Dec. 1980.
40. Vajda FJE, Currie J, Beran J. *Sodium valproate as adjunctant treatment in status epilepticus*. Aust Soc Clin Exper Pharmacol, Canberra Dec 1980.
41. Papanicolaou J, Summers RJ, Vajda FJE, Louis WJ. *Role of central beta2-adrenoceptors in the control of pentylenetetrazol-induced convulsions in rats*. Proc Aust Soc Clin Exper Pharmacol, Adelaide 1981.
42. Papanicolaou J, Summers RJ, Vajda FJE, Louis WJ. *Anticonvulsant effects of clonidine on pentylenetetrazole-induced convulsions in rats*. Proc Aust Soc Clin Exper Pharmacol, Adelaide (1982) 9:473..
43. Summers RJ, Papanicolaou J, Vajda FJE, Louis WJ. *Relationship between alpha2-adrenoceptor selectivity and anticonvulsant effect in a series of clonidine like drugs*. Proc Aust Soc Clin Exper Pharmacol, Adelaide (1981) 9:473
44. Mihaly G, Hanson R, Smallwood R, Anderson J, Vajda FJE. *Effect of H2-receptor antagonist on mixed function oxidase (MFO) mediated drug elimination*. Am Gastroent ASS 1981.
45. Berkovic SF, Bladin PF, Vajda FJE, Jones DB, Smallwood RA. *Hepatotoxicity of sodium valpoate*. Aust Assoc Neurol 1981.
46. Summers RJ, Papanicolaou J, Vajda FJE, Louis WJ. *Enhancement of pentylene-tetrazole induced convulsions following clonidine withdrawal in rats*. Proc Aust Neurosci Soc (1982) 8:583.
47. Papanicolaou J, Summers RJ, Vajda FJE, Louis WJ. *Role of central alpha2-adrenoceptors in control of pentylenetetrazole induced convulsions in rats*. Proc Aust Neurosci Soc (1982) 9:446.
48. Louis WJ, Papanicolaou J, Summers RJ, Vajda FJE. *Relationship between appha2-alpha-adrenoceptor selectivity and enhanced pentylenetetrazol (PTZ) convulsions following chronic administration*. Brit Pharm Soc. 1982.
49. Vajda FJE, Summers RJ, Papanicolaou J, Louis WJ. *Studies of the pathogenesis of pentylene-tetrazol (PTZ) and electroshock induced experimental seizures in relation to central adrenoceptor mechanism*. IXth Int Congr Neuropath, Vienna 1982.
50. Vajda FJE. *Treatment of epilepsy in adults: Application of pharmacokinetic principles*. Meeting of the Royal Australasian College of Physicians, Royal Australasian College of Surgeons and Royal college of Physicians and Surgeons, Sydney 1982.
51. Vajda FJE, Summers RJ, Papanicolaou J, Louis WJ. *Adrenoceptor mechanisms in experimental epilepsy*. Aust Assoc Neurol proc, Sydney 1982.

52. Vajda FJE, Rozitis I, Rutherford D, Jarrott B. *Measurement of plasma clonazepam levels: A comparison of radioimmunoassay (RIA) with gas-liquid chromatography (GLC)*. Aust Soc Clin Exp Pharmacol, Melbourne (May) 1982.
53. Vajda FJE, Papanicolaou J, Summers RJ, Jarrott B, Louis WJ. *Role of beta2-adrenoceptors in the modulation of pentylenetetrazol (PTZ)-induced convulsions in rats*. Aust Soc Clin Exper Pharmacol, Melbourne (May) 1982. (J Clin Exp. Physiol & Pharmac 10:183 [1983]).
54. Summers RJ, Papanicolaou J, Vajda FJE, Louis WJ. *Enhancement of pentylene-tetrazol (PTZ) induced convulsions following clonidine withdrawal in rats*. Neurosci Lett 1982;8:583.
55. Summers RJ, Papanicolaou J, Vajda FJE, Louis WJ. *Role of central alpha2-adrenoceptors in control of pentylenetetrazol (PTZ) induced convulsions in rats*. Neurosci Lett 1982;8:583.
56. Louis WJ, Papanicolaou J, Summers WJ, Vajda FJE. *Relationship between alpha-adrenoceptor selectivity and anticonvulsant activity after chronic clonidine-like drugs in rats*. Proc Brit Pharmacol Soc, Glasgow 1982;59.
57. Berkovic SF, Bladin PF, Jones DB, Smallwood RA, Vajda FJ. *Hepatotoxicity of sodium valproate*. Clin & Experimental Neuro, 1983;19:192-197
58. Berkovic S, Bladin PF, Symington G, Vajda FJE. *Ambulatory 24 hour audio-visual monitoring (Oxford) EEG in man*. Aust Assoc Neurol Proc. Perth 1983.
59. Berkovic S, Bladin PF, Symington G, Vajda FJE. *Plasma prolactin levels after tonic-clonic focal and pseudoseizures*. Aust Assoc Neurol Proc, Perth 1983.
60. Vajda FJ, Burrows GD. *Use of drugs in the treatment of anxiety*. Aust Family Physician, 1983;12(10):714-717.
61. Vajda FJ. *Valproic acid in the treatment of status epilepticus*. Advances in Neurology, 1983;34:519-529.
62. Webster LK, Mihaly GW, Jones DB, Phillips J, Smallwood RA, Vajda FJE. *Contrasting effects of 2Hz antagonists on carbamazepine and valproate pharmacokinetics*. Aust Soc Clin Exper Pharmacol, New Zealand 1983.
63. Marshall AW, Mihaly GW, Smallwood RA, Hanson RG, Vajda FJE, Phillips J, Bladin PB. *Effect of increased bile flow and bile acid secretion on the hepatic elimination of sodium valproate*. Clin Exper Pharmacol Physiol 1984;11:309-317.
64. Berkovic SF, Bladin PB, Copolov D, Maccarrone C, Vajda FJE. *Post-ictal plasma beta-endorphin levels after clinical and experimental seizures*. American Epilepsy Society, San Francisco 1984.
65. Donnan GA, Solopotias T, Rowe P, Kalnins R, Vajda FJE, Mendelsohn FAO. *NMPTB and Parkinsonism: A small animal model*. Proc Aust Assoc Neurol, Abstract 1984.
66. Berkovic SF, Bladin PF, Vajda FJE. *Temporal lobe epilepsy and hyposexual males*. Lancet, 1984;1(8377):622-623.
67. Berkovic SF, Bladin PF, Conneely MD, Gossat LA, Symington GR, Vajda FJ. *Experience with continuous ambulatory EEG monitoring*. Clin & Experimental Neuro, 1984;20:37-46.

68. Vajda FJE, Berkovic S, Rozitis I, Bladin PF, Jarrott B, Woodward J. *Human brain, plasma and cerebrospinal fluid, concentration of clonazepam.* Clin Exper Neurol 1985;21:333.
69. Vajda FJE, Bladin PF, Parsons BJ. *Preliminary clinical experience with clobazam; a 1,5 benzodiazepine.* Clin Exper Neurol 1985;21:177-182.
70. Berkovic S, Maccarrone C, Copolov D, Vajda FJE. *Plasma beta-endorphin in clinical and experimental seizures.* Clin exper Neurol 1985;21:314
71. Vajda FJE. *International clinical experience with 1-deprenyl in Parkinson's disease.* In Vajda FJE, Donnan GA, Burrows GD (eds). *Advances in Parkinson's Disease.* York Press 1985 pp. 30-37.
72. Berkovic SF, Bladin PF, Vajda FJE. *Post-ictal serum prolactin: Value in diagnosis of seizures and pseudoseizures.* XX Congress Canadien des Sciences neurologiques, Montreal 1985.
73. Vajda FJE, Young NA, Lewis SJ, Harris QLG, Jarrott B. *Effect of two benzodiazepines and valproate on kindled amygdaloid seizures in rats.* 3<sup>rd</sup> World Congress of Clinical Pharmacology. Stockholm (July) 1986;959:106.
74. Vajda FJE, Young NA, Lewis SJ, Harris QLG, Jarrott B. *An experimental model of benzodiazepine tolerance in rats.* Aust Assoc Neurol, Hobart (May) 1986.
75. Harris QLG, Lewis SJ, Jarrott B, Young NA, Vajda FJE. *Benzodiazepine effects on the EEG (rat electrocorticogram) - Analysis by three differences in microcomputer techniques.* 3<sup>rd</sup> World Congress of Clinical Pharmacology, Stockholm (July) 1986;960:106.
76. Harris QLG, Lewis SJ, Young NA, Vajda FJE, Jarrott B. *Diazepam dose response effects on the EEG in relation to kindled amygdaloid seizures in the rat.* Aust Soc Clin Exper Pharmacol, Melbourne (Dec) 1986.
77. Harris QLG, Vajda FJE, Jarrott B. *Benzodiazepine effects on the EEG: Choice of microcomputer analysis technique.* Aust Soc Clin Exper Pharmacol, Melbourne (Dec) 1986.
78. Young NA, Lewis SJ, Harris QL, Jarrott B, Vajda FJ. *The development of tolerance to the anticonvulsant effects of clonazepam, but not sodium valproate, in the amygdaloid kindled rat.* Neuropharm, 1987;26(11):1611-1614.
79. Vajda FJ, Lewis SJ, Harris QL, Jarrott B, Young NA. *Tolerance to the anticonvulsant effects of clonazepam and clobazam in the amygdaloid kindled rat.* Clin & Experimental Neurol, 1987;23:155-164.
80. Jarrott B, Vajda FJ. *The current status of monoamine oxidase and its inhibitors.* Med J of Aust, 1987;146(12):634-638.
81. Harris QLG, Vajda FJE, Lewis SJ, Young NA, Jarrott B. *Clobazam dose-response effects on the EEG in relation to kindled amygdaloid seizures in the rat.* Presented to the Australian Neuroscience Society, Newcastle, February 1987. (Abstract in Neurosci. Lett. Suppl37, S81.)
82. Harris QLG, Lewis SJ, Jarrott B, Young NA, Vajda FJE. *Benzodiazepine effects of the E.E.G. (rat electrocorticogram):- Analysis by three different microcomputer techniques.*

Presented at the 3<sup>rd</sup> World Conference on Clinical Pharmacology and Therapeutics, Stockholm, July 1986. (Abstract in *Acta Pharmacologica et Toxicologica*, Suppl V, 1986).

83. Vajda FJE, Young NA, Lewis SJ, Harris QLG, Jarrott B. *Effect of two benzodiazepines and valproate on kindled amygdaloid seizures in rats*. Presented at the 3<sup>rd</sup> World Conference on Clinical Pharmacology and Therapeutics, Stockholm, July 1986. (Abstract in *Acta Pharmacologica et Toxicologica*, Suppl V, 1986).
84. Harris QLG, Young N, Jarrott B, Vajda FJE. *Effect of cyclotizolam on computerized EEG in amygdaloid kindled rats*. *Clin Exper Neurol Proc Aust Assoc Neurol*, Sydney (May) 1988.
85. Harris QL, Lewis SJ, Young NA, Vajda FJ, Jarrott B. *Relationship between the dose-response effects of diazepam and clobazam on electroencephalographic parameters and on kindled amygdaloid seizure activity in rats*. *Clin & Experimental Pharmacol & Physiology*, 1988;15(10):753-764.
86. Harris QL, Lewis SJ, Shulkes A, Vajda FJ, Jarrott B. *Regional brain concentrations of cholecystokinin in the rat: the effects of kindled and non-kindled seizures*. *Neuropharm* 1988;27(5):547-550.
87. Young NA, Lewis SJ, Harris QL, Jarrott B, Vajda FJ. *Differences in the development of tolerance to two anticonvulsant benzodiazepines in the amygdaloid kindled rat*. *Journ of Pharmacy & Pharmacol*, 1988;40(5):365-367.
88. Young NA, Lewis SJ, Vajda FJ, Beart PM. *Effects of the NMDA receptor antagonist MK-801 against amygdaloid-kindled seizures in the rat*. *Experimental Neurol* 1989;103(2):199-202.
89. Beran RG, Vajda FJ. *Weight reduction and epilepsy*. *Med J of Aust*, 1991;154(1):71.
90. Schapel GJ, Bevan RG, Vajda FJE, Berkovic SF, Mashford MC, Yuen AWC, Dunagan FM. *Double-blind placebo controlled crossover study of Lamotrigine in treatment resistant partial seizures*. *International Epilepsy Congress*, Rio de Janeiro 1991.
91. Bladin PB, Vajda FJE. *Flumazenil in Secondary Generalised Epilepsy*. *International Epilepsy Congress*, Oslo 1994.
92. Rodemaker MV, Brodie M, Crawford P, Betts T, Bevan R, Arnjberg D and the Tiagabine Study Group. *An Open-Label Study of the Safety and Efficacy of long-term Tiagabine in patients with epilepsy*. *European Congress for Epilepsy The Haag*, Sept 27 1996.
93. Beran R, Danta G, Somerville F, Berkovic S, Vajda FJE, MacKenzie R, Black A, Robinson M, Buchanan N, The Study Group. *A long-term open label study of the safety and efficacy of tiagabine add-on therapy in patients with uncontrolled epilepsy*. *Meeting of Sci Assoc of Aust Neurol and Assoc of Brit Neurol Sydney (May) 1997*.
94. Vajda FJE. *Monitoring Antiepileptic Therapy*. *Ann Sci Meeting Epilepsy Soc Australia (Oct) 1997*.
95. Beran RG, Berkovic SF, Dunagan FM, Vajda FJE, Danta G, Black AB. *Double-blind placebo-controlled cross-over study of lamotrigine in treatment resistant epilepsy*. *Aust. Assoc Neuro Annual Sci Meeting with Assoc Brit Neurol 29/4/98 - 2/5/98 p.33*.



96. Vajda FJE. *Jungle, Predators and Undergrowth: The Anticonvulsant Jungle*. Festschrift for M. J. Eadie, Brisbane Hospital Health Care publication (July 1997 ).
97. Vajda FJE. *Conventional antiepileptic drugs*. Heritage and New Science Symposium CNS Medicine, Brisbane, July 25-27 1997. ADIS Press p.1-2
98. Vajda FJE, O'Brien TJ. *Modern Treatment of Epilepsy*. Congress of Australian Society of Hospital Pharmacists, Hobart, December 1998.
99. Vajda FJE. *Treatment of Epilepsy*. Deacon Health Care, Geelong, December 1998.
100. Vajda FJE, Angelis-Stoforidis P, Eadie MJ. *Utility of plasma lamotrigine concentrations .Concept of the plasma therapeutic range for individual patients*. Annual Scientific Meeting of European Neurological Society, Milan, June 5-10 1999. J Neurol (1999) 246(Suppl 1: 1/1-1/196 Springer-Verlag 1999.
101. Tomson T, Battino D, Beaussart M, Brodie MJ, Craig J, Lindhout D, Samoli D, Reid S, Sabers A, Schmidt B, Perucca E, Vajda FJE. *Aims, Methods and Organisation*. International Meeting, European Epilepsy Societies, Florence, October 2000.
102. Vajda FJE, O'Brien T, Cook M, Lander C, Hitchcock A. *Australian Registry of Pregnancy Outcomes*. Epilepsy Society of Australia, Melbourne, November 2000.
103. McLean K, O'Brien T, Cook M, Widdop R, Jarrot B, Vajda FJE. *Aggravation of absence seizure by pentylene tetrazole in the genetic absence rat*. Epilepsy Society of Australia Ann. Sci. Meeting. November 2000.
104. Vajda F, Butzkeuven H, Cook M. *Volumetric analysis of magnetic resonance imaging related changes in assessment of progressive cerebral atrophy in multiple sclerosis*. European Neurological Society, Paris, 23 April 2001.
105. Vajda F, McLean K, O'Brien T, Pennefather J, Jarrott B, Kapsa R, Widdop R, Cook M. *A rat model of the aggravation of absence seizures by carbamazepine*. European Neurological Society, Paris, 25 April 2001.
106. Vajda FJ, O'Brien TJ, Hitchcock A, Graham J, Lander C, Australian Centre for Clinical Neuropharmacology, The Victorian Epilepsy Centres and The Department of Medicine, St. Vincent's Hospital Melbourne, Department of Medicine, The University of Queensland. *The Australian Registry of Anti-epileptic Drugs in Pregnancy: Results after two years Suggesting an Increased Risk for Valproate*. Epilepsy Society of Australia, Perth, October 2001.
107. O'Brien TJ, McLean K, Cook MJ, Vosmansky M, Vajda FJE. *Influence of Gender in the Aggravation of Absence Seizures by Carbamazepine in the Low-dose Pentylenetetrazol Rat Model*. Epilepsy Society of Australia, Perth, October 2001.
108. Vajda FJE Lander CM, Hitchcock A, Graham J, O'Brien TJ Solinas C andf Eadaie MJ *Report of the Australian Register of Pregnanci y on antiepileptic drugs: 5years data*
109. Vajda FJE, Lander CM, Hitchcock A, Graham J, O'Brien T, Solinas C, and Eadie MJ Vajda FJE, Lander CM, Cook M, Hitchcock A, Graham J, O'Brien T, Solinas C, and Eadie MJ. *Five year Report of the Australian Pregnancy registry of women on antiepileptic drugs after 52 months*. European Journal of Neurology,11, suppl (2),

September 2004, p.21 Presented at the Congress of European federation of Neurol. Societies Paris, Sept. 2004

### AMERICAN EPI. SOCIETY 2003 ABSTARCT A

- Critical dose-effect relationship between sodium valproate and teratogenicity in pregnancy (F.03) Frank J. Vajda, M.D., F.R.A.C.P.  
Tuesday, December 9, 200 The American Epilepsy Society 57<sup>th</sup> Annual Meeting Boston

110.

110. Vajda FJ, Lander CM, Cook M, Hitchcock A, Graham J, O'Brien T, and Eadie MJ *Australian registry of Pregnancy of Women on Antiepileptic Drugs Journal of Neurology* 251 suppl.3. June 2004, abstract p.48. Presented at the Annual Scientific Meeting of the Europ. Neurol. Soc. Barcelona

111. Sydney

112. F. Vajda<sup>1</sup>, T. O'Brien<sup>1</sup>, M. Cook<sup>1</sup>, A. Hitchcock<sup>1</sup>, J. Graham<sup>1</sup>, C. Lander<sup>2</sup>, and M. Eadie<sup>2</sup> AO.<sup>1</sup> *CRITICAL DOSE-EFFECT RELATIONSHIP BETWEEN SODIUM VALPROATE AND TERATOGENICITY IN PREGNANCY*. Australian Centre For Neuropharmacology, Raoul Wallenberg Centre, St. Vincent's Hospital, Fitzroy, Victoria, and <sup>2</sup>Department of Medicine, The University of Queensland, Brisbane, Queensland.

113. AES 2003 Cleveland

114. NZ 2003 Auckland

115 Panel AES 2003 Philadelphia

116. Vajda FJE, Lander CM, Cook M, Hitchcock A, Graham J, O'Brien T, Solinas C, and Eadie MJ. *Report of the Australian Pregnancy registry of women on antiepileptic drugs after 52 months*. *European Journal of Neurology*,

117. Vajda FJE, Lander CM, O'Brien TJ, Hitchcock A, Graham J, Solinas C, Eadie MJ and Cook M. *Australian Pregnancy Registry of Women on AEDs; Results to 31 December 2003* Abstract, Accepted for presentation at the American Epilepsy Society Annual Meeting, New Orleans, December 2004

118. Vajda FJE, By invitation. *Multimodal Therapy in Neurodegenerative Disease* Neuropharmacology Teaching Session (Co-Chair with Korczyn, Amos). WCN, Sunday 4.11.05. S

119. EURAP Central Project Commission. Tomson P, Perucca E, Battion D, Lindhout D, Sabers M, Vajda FJE. *Seizures observed associated with the EURAP Registry in pregnancy* *Intern. Epilepsy Congress Paris Sept, 2005*

120 Vajda FJE. *New developments in the pharmacology of epilepsy*. Australian Soc. Clin. Exp. Pharmac. And Toxicology, Melbourne Dec 2005

121. Vajda FJE, Lander CM, Hitchcock A, Graham J, O'Brien T, Solinas C, and Eadie MJ. *Five Year report of the Australian Pregnancy Registry for Women on Antiepileptic Medication.* World Congress of Neurology, Sydney November 10 2005

122. *Report of the Australian Pregnancy registry of women on antiepileptic drugs after 52 months.* European Journal of Neurology, 11, suppl (2), September 2004, p.21. Presented at the Congress of European federation of Neurol. Societies. Paris, Sept. 2004.

123 Vajda FJ, Lander CM, Hitchcock A, Graham J, O'Brien T, and Eadie MJ *Australian registry of Pregnancy of Women on Antiepileptic Drugs.*Journal of Neurology 251 suppl.3. June 2004, abstract p.48 Presented at the Annual Scientific Meeting of the Europ. Neurol. Soc. Barcelona

125 Cairns

126. EURAP Tomson T Perucca E Battion D Lindhout D Sabers. *EURAP report on seizure v related observations fromn the Reigistry.* Epilepsia 2005 , submitted.

127 AES 2003

128 NZ 2003

128 Panel AES 2003

129 Aes 2004

130. Vajda FJE Lander CM, O'Brien TJ, Hitchcock A, Graham J, Solinas C, Eadie MJ. *Australian Pregnancy Registry of Women on AEDs; results to 31.december 2003*, Abstract, Accepted for presentation at the American Epilepsy Society Annual Meeting, New Orleans, December 2004

131. Vajda FJE and Eadie MJ. *New developments in the pharmacology of epilepsy. New issues, new armamentarium.* ASCEPT Annual Meeting (by invitation). Dec 4-5 2005 Melbourne.

132. Vajda FJE , By invitation. *Multimodal Therapy in Neurodegenerative Disease Neuropharmacology Teaching Session ( Chair).* World Congress of Neurology Sydney November 2-5 2005.

133. EURAP Central Project Commission. Tomson P, Perucca E, Battion D, Lindhout D, Sabers M, Vajda FJE. *Seizures observed associated with the EURAP Registry in pregnancy Intern.* Epilepsy Congress Paris Sept, 2005.

134 Beran R, Spira P, and the Gabapentin Chronic Daily Headache Group. *Novel Therapies of Brain Mechanism in Migraine and Cluster the Headache.* American Academy of Neurology, Las Vegas, 9 May 2001.

135. Vajda FJ, Lander CM, Hitchcock A, Graham J, O'Brien T, and Eadie MJ *Australian Registry of Pregnancy of Women on Antiepileptic Drugs : 75 months data.* Australian Assoc. Neurol Annual Sci. meeting Canberra, May 2006

136 Vajda FJ, O'Brien T, Lander CM, Hitchcock A, Graham J, , and Eadie. *Dose related foetal malformations: study of the effects of AEDs in the Pregnancy Register*. Australian Assoc. Neurol Annual Sci. meeting Canberra , May 2006

137 . Vajda FJE, Hitchcock A, Graham J, O'Brien T, , Lander CM, and Eadie MJ  
Epileptic seizure corol in pregnancy  
J.Neurology 2007 ;254iii33. Abstract 0138, Rhodes June 2007

138 EURAP Central Project Commission. Tomson P, Perucca E, Battion D, lindhout D, Sabers, Vajda FJE  
Treatment of status epilepticus in pregnancy  
7<sup>th</sup> Eurpean Congress of Epileptology , Helsonki 2-6 Jul, 2006, Epilepia may 2006.

139 Vajda FJE, Hitchcock A, Graham J, O'Brien T, , Lander CM, and Eadie MJ  
Annual Report submitted ANZAN Brisbane 2008-02-19

140 . Vajda FJE, Hitchcock A, Graham J, O'Brien T, , Lander CM, and Eadie MJ  
Changing patterns of risks, malformations and prescribing  
ANZAN Brisbane 2008-02-19 poster presentation

140 Vajda FJE, Graham J, Hitchcock AA, Lander CM, O'Brien TJ and Eadie MJ  
Changes in prescribing patterns; observations on polytherapy v. monotherapy from the Australian Pregnancy Register ,  
Epilepsy Society nua Scientific Meeting , Sydney Nov 6-9 , 2008

142 29th International Epilepsy Congress ROME ,AUGUST 2011  
· Abstract: A-376-0001-00675 ·  
Wood AG Nadebaum C, Anderson VA, Reutens DC, Barton S O'Brien T, Vajda FJE  
Valproate dose is an independent risk factor for autism spectrum disorder: Evidence from  
prospective assessments in the Australian Brain, Cognition and Antiepileptic Drugs study

143Is valproate an obligatory teratogen or is ii a dose issue  
6<sup>th</sup> World Congress onContraversies in Neurology  
Barcelona 26-31.10. .2010 Platform presentation

144"Second Generation of Antiepileptic Drugs (AEDs)  
Data from Report on the

from the Database of the Australian Pregnancy Register (APR)  
Oceanic and EpiLEpsy Society of Australia  
Annual Scientific Meeting  
Melbourne October 2010

145Vajda F, Graham J, Hitchcock, RotenA, Lander CM, O'Brien TJ, and Eadie MJ  
Report from the Australian Register Of Pregnancy  
International Society for Obstetrics Medicine  
Melbourne 2010

.146 Vajda FJ, Lander CM, Hitchcock A, Graham J, O'Brien T, and  
Eadie MJ  
World Congress of Internal Medicine  
Melbourne 2010

147ANZAN 09,

1480 10

14 9ESA 09,

150 010

151Keller N/Science trails ADD

152 Prague \* see anbstract

153EURAP Study Group

154 Pregnancy outcomes and mode of delivery in EURAP

International Epilepsy Congress

Budapest August 2009

155 Second Generation of antiepileptic drugs

ILEA World Congress Rome August 2011

Vajda FJ, Graham JE, Roten A, O'Brien TJ, Lander CM, Eadie MJ.

Second generation of Antiepileptic Drugs

Report from the Australian Pregnancy register

Rome , Epilepsy World Congress August 28-Sept2, 2011

Abstract, accepted for publication, May 2011

#### D. Recent Presentations:

Vajda FJA, O'Brien TJ, Thomson T and Savalescu J: Forum on pregnancy registry and women's issues. Annual Scientific Meeting of the Epilepsy Society of Australia, Session 3, 15-18 November 2000.

McLean K, O'Brien TJ, Pennefather J, Kapsa R, Widdop R, Cook M and Vajda FJE: A rat model of the aggravation of absence seizures by carbamazepine. Annual Scientific Meeting of the Epilepsy Society of Australia, Session 2, 15-18 November, 2000.

Vajda FJE: Inaugural Peter Bladin Historical lecture by Keith Henderson: Contribution of A. Schuller to Australian Neuroscience. Annual Scientific Meeting of the Epilepsy Society of Australia, Session 3, 15-18 November, 2000.

Vajda FJE: Directions in Clinical Pharmacology, Howard Florey Institute of Experimental Physiology and Medicine, University of Melbourne, August 2000.

Vajda FJE: Chairman, "Added seizure control" discussion panel. Teleconference, October, 2000.

Vajda FJE: Epilepsies: Acute emergencies, Epilepsy Foundation of Victoria, June 2000.

Vajda FJE, O'Brien TJ, Hitchcock A, Graham J, Cook M, Lander C: Establishment of a prospective nationwide study of the consequences of the use of antiepileptic drugs in pregnancy. Epilepsy Society of Australia, November, 2000.

Vajda FJE (convenor), Collins S, Thyagarajan D, Sedal L, Paine N, Cook M, Byrne E, Taylor B and O'Brien TJ: Continuous home evaluation of clinical knowledge, Royal Australian College of General Practitioners: Neurology 342-343, 1-27 (2000).

Vajda FJE Seizure aggravation and polycystic ovaries; Sanofi Symposium Sydney, July 2001

Vajda FJE Antiepileptic Drugs, Pregnancy and Polycystic Ovaries  
Epilepsy Society of Australia Annual Scientific Meeting  
Perth October 15-19, 2001

McLean K, O'Brien T, Lawrence A, Cook MJ Vosmansky M and Vajda FJE  
Seizure aggravation by carbamazepine in the PTZ kindled rat: gender differences  
Epilepsy Society of Australia, Ann. Scientific Meeting, Perth, 2001

Vajda FJE O'Brien T, Cook MJ and Lander C  
Australian Pregnancy Registry for Women on Antiepileptic Drugs  
Report of possible increased frequency of malformations on valproate  
Epilepsy Society of Australia, Ann. Scientific Meeting Perth October 2001.

Vajda FJE Chair: International Meeting; Optimising Antiepileptic Therapy,  
Perth October 15, 2001

Vajda FJE, Genton P, Stodartek M, Somerville E, Berkovic S, and McLaughlin D  
Safety Issues in Therapy Panel Discussion, ESA Satellite Meeting Perth 2001

Vajda FJE Valproate: International Symposium Goteborg Sweden May 2005

Vajda FJE Advance Trainees Scientific Symposium, Sydney, Feb 2005

Vajda FJE Methods in Neuropharmacology, Masters of Neuroscience Training  
Course, Austin Hospital Melbourne March 2005

Current Trends in management of Parkinson;s Disease  
Pharmaceutical Society of Australia, Melbourne  
March 2008

Vajda FJE

### **Current Board Memberships:**

Drugs in Research and Development, (ADIS) Editorial Board

Central Project Commission, European Register of Antiepileptic Drugs for Women  
with Epilepsy in Pregnancy Intern. League against Epilepsy

Australian Prescriber, Editorial Board

Neuroscience Trials, Australia

Degeneration and Regeneration , Editorial Board

Faculty of 100 – International panel of expert opinion and education in  
Epilepsy,  
chaired by E. Perucca



**Hospital Committees (1975-1988):**

Member of Drug Committee, Austin Hospital.

Therapeutic Trials Committee, Austin Hospital.

Oncology Group, Austin Hospital.

Pharmacopoeia Subcommittee and Editorial Board, Austin Hospital.

Drug Bulletin, Austin Hospital.

Cyclotron Working Party, Austin Hospital.

Parenteral Nutrition Group, Austin Hospital.

**Referee of articles for Scientific Journals 2005-2011**

J Clin Neuroscience

Epilepsia

American Journal of Obstetrics

J Neuroscience

Acta Neurologica Scandinavica

Prescriber Journal

Drugs

Drugs in Research and development

Future Drugs

Epilepsy Research

J Degeneration and Regeneration

Med J Australia

Therapeutic Drug Safety

**Referees:**

Mervyn Eadie AO PhD. MD FRCP (Ed.) FRACP

Emeritus Professor of Neurology and Clinical Neuropharmacology  
Department of Medicine  
University of Queensland  
Royal Brisbane Hospital

Professor Geoffrey A Donnan AO MD FRACP  
Director of Howard Florey Institute of Neurosciences  
Royal Pde. Parkville 3052  
Institute

Professor Edward Byrne AO.D.Sc. MD FRCP (Ed.) FRACP)  
Vice Chancellor of Monash University  
Clayton, Victoria, Australia, former  
Executive Dean of Medicine,  
University College Hospital and Research Centre Conglomerate  
University of London, UK.

Jerome E. Engel Jr. III MD PhD  
Past President, International League Against Epilepsy  
Professor of Neurology  
Department of Neurology  
and Brain Research Institute  
UCLA School of Medicine  
Los Angeles CA USA  
Phone: 0011 1 310 825 5745  
E-mail: [engel@ucla.edu](mailto:engel@ucla.edu)

Professor TJ Martin AO FRS FAA MD DSc FRACP LLD  
c/ St. Vincent's Hospital Institute for Research  
Fitzroy 3065  
Melbourne